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With the cost of healthcare in the U.S. predicted to reach 30% of the GDP by 2040, 
medical technology needs to help reduce the stress on physicians and facilitate 
personalized preventive care.  The two most promising ways of achieving this are 
through developments in implantable devices for monitoring and treating patients 
outside of clinical settings and through better point-of-care diagnostics tools.   
The first part of this dissertation focuses on the development of a potentially 
implantable autonomous device for the prevention of late-phase hemorrhagic shock 
(HS), the leading cause of death for people with traumatic injuries. We demonstrate that 
such a device can continuously monitor vasopressin levels, an indicator of late-phase 
HS, and release vasopressin automatically when levels drop below a certain threshold 
in order to help stabilize the situation. We also discuss the possibility of using a non-
enzymatic glucose fuel cell unit, instead of a lithium battery, in order to increase the 
implantable device’s lifetime. Novel power sources are important in the development of 
low-power long-term implantable devices, and we propose several non-enzymatic fuel 
cells that can be used as coating layers on current implantable devices or as stand-alone 
power sources. We show that such glucose fuel cell can produce 16µW cm-3 of power 
 iv 
and can be integrated in implantable devices such as the one for preventing late-phase 
HS.  
In the second part of the dissertation, we discuss the development of a platform for 
colorimetric biomarker detection on a smartphone. This platform consists of a 
smartphone accessory that allows uniform and repeatable image acquisition of a 
colorimetric test strip and an app that analyzes parameters such as hue, saturation and 
luminosity of the test area, quantifies the biomarker levels and displays the value on the 
screen. We demonstrate its use in monitoring electrolyte loss, enamel decalcification, 
cholesterol and vitamin D. We envision this as the first step toward the development of 
the NutriPhone, a platform for vitamin and micronutrient testing on a smartphone.   
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Chapter 1 
Opportunities in point of care diagnostics1 
 
This thesis focuses on the development of two alternative technologies for point of care 
diagnostics and preventive care. With health care cost in the U.S. projected to reach 30% 
of GDP by 2040, it is clear that technology needs to play a major role in the future. In 
this section we will discuss briefly some of the ways through which the reliance on 
physicians and hospital care can be reduced as well as analyze some of the areas where 
medical technology can play a major role in the near future. 
 
 
 
 
 
 
1Section 1.2 of this chapter was published as Chen,Y.-F., Jiang, L. *, Mancuso, M. *, Jain, 
A. * , Oncescu, V*,  Erickson, D. "Optofluidic Opportunities in Global Heath, Food, 
Water and Energy” Nanoscale 4, 4839-4857 (2012)   
* These authors have contributed equally to this paper 
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1.1 Autonomous Implantable Devices for Preventive Care 
Over the past decade, implantable autonomous microsystems have been developed to 
counter life-threatening medical conditions and to improve patient care by replacing 
cumbersome treatment procedures. (Receveur et al., 2007)As such, a growing number of 
patients now depend on implantable cardioverter defibrillators (Adler et al., 2013), 
gastric stimulators (Arriagada et al., 2011), cardiac pacemakers (Liu et al., 2013) and 
artificial organs (Cebotari et al., 2010; Krabatsch et al., 2011; Ricotti et al., 2012) for 
survival. In such cases, the severity and urgency of the medical condition override the 
high cost and risk of the invasive surgery that is required. On the other hand, some 
situations call naturally for implantable medical devices to continuously monitor 
physiological changes in patients or to deliver treatment through pre-determined and 
repeated drug delivery. For instance, continuous glucose monitoring devices have 
found their market by increasing the efficacy of diabetes treatment and by helping 
patients monitor real-time variations in their blood glucose levels due to insulin and 
food intake, exercise, and other factors. Recently, Farra et al. demonstrated an 
implantable drug delivery microchip that operates for up to 3 weeks and eliminates the 
need for daily physician-assisted injections for patients with osteoporosis (Farra et al., 
2012). While these developments have been successful at independently performing 
sensing (Fojtik et al., 2013) and drug delivery (Chung et al., 2009), developing 
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implantable medical devices capable of achieving both of those functions 
simultaneously would be suitable for a number of applications (Esquivel et al., 2012). 
One such case is the detection and treatment of traumatic injuries such as hemorrhagic 
shock (HS).   
In Chapter 2 we discuss in detail the development of a autonomous device for 
application in late-phase HS prevention that consists of a nanowire biosensor for 
detecting changes in vasopressin levels, an on-board electrochemically driven drug 
delivery system for administration of vasopressin, and a non-enzymatic glucose fuel 
cell for powering the system. 
 
1.1.1 Glucose Fuel Cells for Implantable Devices        
For over three decades, low-power implantable devices have been powered using non-
rechargeable lithium batteries (Vincent, 2000) that have a lifespan of 5 to 10 years for 
low-power drain devices such as pacemakers but can only operate for up to a year at 
power-densities above 45W/cm3 (Roundy et al., 2003). Therefore alternative power 
sources are required for the long-term operation of the implantable devices currently 
being developed (Chung et al., 2008; Ebel et al., 1996; Federspil and Plinkert, 2004; 
Jalilian et al., 2007; Salam et al., 2010; Vaddiraju et al., 2010; Zafar Razzacki, 2004). 
Although remote powering of implantable devices is in theory possible using 
transcutaneous energy transmission systems (Joun and Cho, 1998; Miura et al., 2006), in 
 4 
many situations it is desirable to develop autonomous implantable devices that do not 
require any external power input. Alternative approaches considered for internally 
powering autonomous implantable devices include: microbial and enzymatic bio fuel 
cells (Bullen et al., 2006; Davis and Higson, 2007; Logan and Regan, 2006; Minteer et al., 
2007), abiotic fuel cells (Kerzenmacher et al., 2008a), thermal power sources (Yang et al., 
2007) and vibrational energy convertors (Cook-Chennault et al., 2008; Gao et al., 2007; 
Wang, 2006). Abiotic glucose fuel cells (Drake et al., 1970; Kerzenmacher and 
Sumbharaju, 2007; Rao and Richter, 1974) are promising because they offer reasonable 
performance and higher stability than enzymatic (Barton et al., 2004; Mano et al., 2003) 
and microbical glucose fuel cells (Chaudhuri and Lovley, 2003; Rabaey and Verstraete, 
2005). Although they offer better stability, thermal power sources and vibration energy 
convertors have a theoretical power limit that is too low for many implantable devices 
currently under development.  
In Chapter 3, we present a novel abiotic glucose fuel cell that uses a stacked electrode 
design in order to achieve glucose and oxygen separation.  An important characteristic 
of the fuel cell is that it has no membrane separating the electrodes, which results in low 
ohmic losses and small fuel cell volume.  For reason further described in Chapter 3, this 
fuel cell has a lot of potential as a coating layer for existing implantable devices, 
however it is not suitable for low volume applications where.  
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In Chapter 4, present single-layer fuel cell with good performance (2µW cm-2) and 
stability that can be stacked to obtain a high volumetric power density (over 16µW cm-
3).  This represents the first demonstration of a low volume non-enzymatic fuel cell stack 
with high power density, greatly increasing the range of applications for non-enzymatic 
glucose fuel cells. 
 
1.2 Nutrition and Health Monitoring 
With the increase in obesity and cardiovascular problems in the developed world, 
nutrition monitoring has become a major concern.  In addition, studies have shown that 
nutritional status affects a patient’s response to illness and is even related to a reduced 
functional capacity of elderly people (Oliveira et al., 2009). 
Despite the increase in public awareness, there have been few changes in the methods 
of nutritional assessments. Typically, a brief nutritional screening, including a physical 
examination, is used to identify patients in need of in-depth analysis. Despite their 
importance, nutritional assessments are not common among the general populations, 
and consequently, deficiencies in calories, proteins, essential fatty acids, vitamins, and 
minerals often go unnoticed.  
There are few methods for in-vivo nutritional monitoring since food analysis methods 
are either too invasive for continuous monitoring or too difficult to miniaturize for on 
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chip applications.  However, a few methods, mainly optical, have been adapted for 
monitoring living tissues.  The advantage of optical methods for in-vivo applications lies 
in the fact they are potentially less invasive than mechanical or electrical methods for 
nutrient detection. Some groups have demonstrated the potential of optical methods for 
monitoring the evolution of nutrients on the skin, which is possible because infrared 
light can travel through tissues and interact with the various components of the skin. 
(Stamatas and Kollias, 2011) These interactions can alter the intensity, spectral 
composition and direction of the reflected light that can be collected and analyzed. The 
information that can be obtained using purely optical methods on the skin, however, is 
limited because primary nutrients are quickly broken down to their constituents during 
digestion prior to entering the bloodstream. Consequently, several groups have 
developed optofluidic methods for analyzing body fluids such as blood and sweat on 
chips. (Curto et al., 2011) Methods for collecting body fluids including micro-needles 
(Zahn et al., 2005) and sweat-patches(Kintz et al., 1996) have been developed in parallel. 
The lab-on-a-chip approach is more versatile because it allows both optical and non-
optical sensing methods to be integrated in a common device. 
 There is a real need for nutritional assessment devices that can evaluate nutritional 
deficiencies in patients more rapidly and regularly without relying heavily on 
physicians.  In the following sections we review the advances in in-vivo optofluidic 
monitoring in the areas that will likely see rapid innovations in the coming years.   
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1.2.1 Continuous glucose monitoring for diabetes  
Accurate carbohydrate detection, in particular glucose detection, has been a priority for 
several decades because of the prevalence of diabetes in the world. (Mohan et al., 2007) 
While this has led to the development of fingerpick tests, accurate and reliable 
continuous glucose monitoring devices are still not well established. Continuous 
monitoring of glucose is important because it could prevent issues associated with long 
periods of hyper- and hypoglycemia. (Ricci et al., 2005) Current FDA-approved needle-
type amperometric enzyme electrode devices that monitor glucose continuously such as 
the ones commercialized by Medtronic require frequent replacement of the enzyme 
needle. (Hussain et al., 2005) Thus, there is an opportunity for the development of 
minimally invasive optical sensors that can last much longer without the need for 
replacing parts. 
Yuen et al. demonstrated that SERS can be used for monitoring glucose levels in vivo. 
(Yuen et al., 2010) In this case, a sensor chip was functionalized and implanted 
subcutaneously in a rat, and glucose concentrations in the interstitial fluid were 
monitored by measuring the surface-enhanced Raman spectra through the skin using 
spatially offset Raman spectroscopy (SORS). The authors suggested that the 
combination of SERS and SORS is a powerful technique that can be applied to in vivo 
sensing of other biological targets.  Currently, the disadvantage of this approach is the 
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high cost required for the optical components in such a device. 
In vivo glucose detection has also been demonstrated using a functionalized hydrogel-
optical fiber, where the detection is based on the glucose-induced contraction of the 
hydrogel. (Tierney et al., 2009) The hydrogel was fabricated on the end of an optical 
fiber, and the optical length was measured using an interferometric technique. Another 
promising method for in vivo glucose monitoring is single wall carbon nanotubes 
(SWNT) fluorescence because the photostability and near IR characteristics of SWNT 
fluorescence avoid in-vivo transmission and sensor lifetime issues. Barone et al. has 
developed two SWNT-based sensors: an enzyme based sensor and an affinity based 
sensor.(Barone et al., 2004) The Liepmann group at the University of California at 
Berkeley has developed an electrochemical device that allows for continuous 
monitoring of glucose. (Zimmermann et al., 2003) The device incorporates a micro-
needle patch that draws interstitial fluid onto a chip with incorporated electrochemical 
sensors. 
 
1.2.2 Identifying deficiencies in protein and essential fatty acids  
The importance of a balanced diet containing adequate amounts of proteins and 
essential fatty acids is well known, however due to the lack of continuous nutritional 
monitoring methods deficiencies often go unnoticed. Studies have shown low levels or 
imbalance of essential fatty acids can lead to increases in blood viscosity, vasospasm, 
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and vasoconstriction and can result in increased risk of several illnesses including 
osteoporosis. (Kruger and Horrobin, 1997; Simopoulos, 1999) Protein deficiencies, 
common in both developing and developed countries, can cause a variety of health 
issues including mental retardation.(Latham, 1997)  
Several groups have developed methods for in vivo monitoring of essential amino acids. 
Most methods make use of microdialysis and capillary electrophoresis (CE) 
techniques.(Sandlin et al., 2005; Zuo et al., 1995) Microdialysis is a popular method 
because it allows for good temporal resolution. It has been used to investigate 
neurotransmitters in the brain extracellular fluid and drug delivery.(Kennedy et al., 
2002) Following microdialysis, the sample is investigated using either liquid 
chromatography(LC) or CE, which has been shown to require smaller sample volume 
and therefore offer better temporal resolution than LC.  Zhou et al. was one of the first 
to develop a separation based biosensor capable of near real-time analysis of aspartate 
and glutamate.(Zuo et al., 1995) Following microdialysis sampling, the primary amine 
analytes were derivatized before traveling to a microinjection valve and reaching the CE 
column. Using this system, sample amino acids from brain dialysate were analyzed 
with a temporal resolution of less than 2 minutes and a detection limit of 0.1µM.  More 
recently, microchip devices for amino acid monitoring with improved temporal 
resolution, miniaturization, and fluid handling capabilities have been demonstrated. 
(Nandi et al., 2010; Wang et al., 2010) Dialysis based techniques in conjunction with CE 
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are useful in the detection of analytes that cannot be detected using conventional 
biosensors.  
Measuring fatty-acid levels in tissue usually involves time consuming processes for 
extraction and analysis such as gas chromatography.(Liu, 1994) Yoshida et al. developed 
a direct method for measuring dietary fatty acids on human lips using Fourier 
transform infrared spectroscopy (FTIR) with attenuated total reflection (ATR).(Yoshida 
et al., 2009) The lips were chosen since they are unaffected by sebaceous activity that 
could mask changes in lipid composition following ingestion of fatty acids.  The 
transport of docosahexaenoic acid (DHA) from blood vessels to the lips is very rapid 
and can be detected less than 2 hours after the intake of foods containing DHA.  It is 
noted that, because the lip surface in humans is unique, with less barrier functions than 
normal skin and blood vessels in the dermis, the transport of biomaterials from blood 
vessels to the lip surface is more rapid than to other skin surfaces, thus being ideal for 
the optical detection of a variety of nutrients. 
 
1.2.3 Salts, minerals and vitamin monitoring  
Measuring ion concentrations directly in bodily fluids such as sweat can be correlated 
to electrolyte concentrations in plasma.  The Diamond group at Dublin City University 
has developed a textile based patch with integrated optical detection system for sweat 
monitoring.(Morris et al., 2009) The device consists of a fluid handling system that 
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collects the sweat inside a narrow channel that flows over an area with an immobilized 
pH sensitive dye. A paired emitter-detector dual LED is used to provide continuous 
quantitative measurements of pH. This approach has several potential applications, 
including measuring sweat rate during exercise.(Coyle et al., 2010) In addition, the sweat 
contains other biomarkers that can be used to estimate nutrients levels in the interstitial 
fluid. 
Sweat monitoring has already found commercial applications for drug (Bush, 2008) and 
cystic fibrosis testing. (LeGrys et al., 2007) Developing microfluidic devices for 
continuous monitoring of potassium, sodium, and chloride ion concentration could be 
the next step. 
Vitamins are essential compounds that cannot be synthesized in high enough quantity 
by the body and need to be obtained through diet. Kokaislova et al. recently 
demonstrated the application of Fourier transform SERS spectroscopy for the detection 
of B-group vitamins riboflavin, nicotinic acid, pyridoxine, and folic acid on both gold 
and silver surfaces.(Kokaislová and Matějka, 2012) In addition, there are few methods 
for simultaneous determination of several kinds of fat-soluble vitamins in biological 
fluids.  However, these methods, such as HPLC analysis using diode array detection, 
usually involve time consuming steps that are not suitable for in vivo 
applications.(Klejdus et al., 2004) Mata-Granados et al. proposed a fully automated 
method for determining fat soluble vitamins and vitamin D metabolites in serum.(Mata-
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Granados and Gómez, 2009) After a multistep separation process, ultraviolet detection 
was performed at several wavelengths for each target. 
 
1.3 Smartphone Diagnostics  
As discussed in section 1.2, there are numerous scientific developments in the areas of 
personal nutrition and health monitoring, which is not surprising given high 
commercial potential of such technologies. However in many cases, those technologies 
require time-consuming protocols, advanced laboratory infrastructure and trained 
personnel that is hard to translate to the consumer market.9 In many cases the biggest 
challenge is the need for low-cost readers to quantify the colorimetric reactions of such 
immunoassays. Smartphones have the potential of solving this issue. The immunoassay 
colorimetric reactions could be imaged directly on a smartphone and the processed data 
can be stored for tracking or sent via e-mail directly to a physician. Increasingly 
sophisticated camera technology on smartphones can also improve the accuracy of 
quantifying such colorimetric reactions. 
A high-impact area for mobile health, that has not yet taken off commercially, is in the 
development of biochemical portable diagnostics tools3. Smartphone accessories for the 
detection of biomarkers in bodily fluids could greatly reduce the cost of medical testing 
and increase global access to healthcare. Several academic groups are currently 
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developing smartphone platforms for biomarker detection. Recently, Coskun et al. 4 
have developed a testing platform that can be used at home to test foods for peanut 
traces and other common allergens. Several other groups are working on smartphone-
based image processing for quantifying colorimetric changes on paper-based 
immunoassays5.  
In chapter 5, we demonstrate an integrated smartphone accessory for monitoring 
changes in sweat and salivary pH.  
In chapter 6, we show that we can use such a system for the quantification of cholesterol 
levels in blood. Through a series of human trials we demonstrate that the system can 
accurately quantify total cholesterol levels in blood within 60 sec by imaging standard 
test strips. 
In the Conclusion and Future Work chapter, we discuss the development of the 
NutriPhone, a platform for vitamin and micronutrient analysis on the smartphone. As a 
first application, we perform a vitamin D measurements by evaluating serum samples 
with unknown 25(OH)D concentration and comparing the results to those obtained 
using a commercial ELISA method. 
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Chapter 2 
 
Autonomous device for application in late-phase 
hemorrhagic shock prevention  
 
2.1 Abstract 
Hemorrhagic shock (HS) is the leading cause of death for people with traumatic 
injuries. The onset of HS is correlated with marked changes in the plasma vasopressin 
levels and some studies indicate that administrating vasopressin in the bloodstream can 
help stabilize the situation. This situation calls naturally for the use of implantable 
devices for both the monitoring and treatment of HS. In this work, we present a self-
powered hemorrhagic-shock autonomous integrated device (hemoAID) that 
continuously monitors vasopressin levels and releases vasopressin automatically when 
levels drop below a certain threshold. We demonstrate that the device can operate at 
physiological concentrations of vasopressin, in sheep serum, thus paving the way 
towards the development of an autonomous implantable device for HS prevention. 
1 This chapter was published as:  Vlad Oncescu*, Seoho Lee*, Abdurrahman Gumus, 
Kolbeinn Karlsson, David Erickson “Autonomous device for application in late-phase 
hemorrhagic shock prevention”. Under review in PLOS ONE  
* These authors have contributed equally to this paper 
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2.2 Introduction 
Studies have correlated the onset of HS with marked changes in the plasma vasopressin 
levels (Morales et al., 1999; Voelckel et al., 2010). Morales et al. have conducted a set of 
canine experiments where vasopressin levels showed a marked increase at the onset of 
hemorrhage (to as much as 319pg/mL) followed by a fall to well below the normal 
physiological level (29pg/mL) as hemorrhage progressed (Morales et al., 1999). In 
addition, evidence suggests that replenishment of vasopressin at this stage can reverse 
hypotension in patients (Anand and Skinner, 2012; Wenzel et al., 2008). Krismer et al. 
have reported case studies where dosages of 100 – 160 IU vasopressin led to 
hemodynamic stability with sinus rhythm in HS patients within 2min and patient 
survival without additional treatment of up to 90min (Krismer et al., 2005). Therefore, 
vasopressin can serve as both a biomarker indicative of a critical injury state and a 
therapeutic agent for treating it. Developing an implantable autonomous device that 
can provide initial medical treatment when physician care is not readily available is 
highly suitable in this case. 
In this chapter, we present a self-powered hemorrhagic-shock prevention autonomous 
integrated device (hemoAID) that continuously monitors vasopressin levels in solution 
and releases vasopressin automatically when vasopressin levels drop below a certain 
threshold. We demonstrate that the device works at physiological concentrations of 
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vasopressin in sheep serum. This represents the first steps towards the development of 
an implantable, self-powered microfluidic device for late-phase HS prevention. In the 
next sections, we introduce the hemoAID and discuss the fabrication and integration of 
its major components. We then demonstrate the operation of the device during rapid 
changes in vasopressin concentration and proceed by discussing the characteristics of 
the sensing, drug delivery and power units. Finally in the “Conclusion and Future 
Prospective” section, we discuss some of the issues that need to be addressed in order 
to move toward a fully integrated autonomous implantable hemoAID. 
 
2.3 Materials and Methods   
2.3.1 System Design and Assembly  
The hemoAID device shown in Fig. 2.1a consists of a nanowire biosensor for detecting 
changes in vasopressin levels, an on-board electrochemically driven drug delivery 
system for administration of vasopressin, and a non-enzymatic glucose fuel cell for 
powering the system. Those three main functional components are integrated inside a 
3cm3 package. In this prototype version, the electronic control system is external to the 
system and uses the circuit shown in Fig. 2.1b. External housing of the circuitry was 
done to facilitate prototype development and could be integrated into the system in the 
future. The non-enzymatic glucose fuel cell is used to continuously charge a small  
 17 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 hemoAID device for late-phase HS prevention a) Integrated device 
consisting of a biosensor, drug delivery and fuel cell unit b) schematic of the electrical 
connections between the different components of the hemoAID  
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rechargeable battery (Thinergy MEC225) that is then used to power a low power 
microcontroller (MSP430F2012, Texas Instruments, TX, USA). This set-up allows the 
device to operate steadily even with significant fluctuations in the power output of the 
fuel cell unit. During device operation, the sensor is driven by an adjustable 2-terminal 
current source (LT3092, Linear Technology, Milpitas, CA, USA) at 60mA. The resistance 
of the sensor changes with the amount of vasopressin in solution, which results in 
detectable voltage change over the biosensor. In order to improve sensitivity, the 
voltage is amplified using a non-inverting amplifier (Maxim Integrated, CA) before 
being detected using a low power microcontroller’s analog to digital converter (ADC). 
If the voltage is lower than the pre-determined threshold, the microcontroller enables 
the corresponding output pin to activate the drug delivery system. In order to increase 
the discharge rate of vasopressin in the drug delivery device, the base voltage (3V) is 
converted to 35V with a micropower step-up DC/DC converter (LT3464, Linear 
Technology, Milpitas, CA, USA). 
 
2.3.2 Biosensor fabrication  
The biosensor consists of gold electrodes and a carbon nanotube (CNT) based detection 
region on which aptamer molecules are immobilized (He et al., 2013). The detection 
region of the sensor was patterned on a 4-inch silicon wafer using general 
photolithography and surface-treated with (3-aminopropyl)trimethoxysilane (APTMS) 
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using Molecular Vapor Deposition Tool (MVD 100). The aminosilanes from the surface 
treatment were covalently linked with COOH-functionalized multiwalled CNT (Cheap 
Tubes Inc.) to serve as carriers of aptamer receptors. The scanning electron microscope 
(SEM) images of immobilized CNT have been reported in our previous work (He et al., 
2013). Electrodes to the detection zone were lithographically patterned, followed by 
5nm chromium/60nm gold deposition using a CHA Mark 50 e-Beam Evaporator. The 
wafer was diced into 0.8cm x 0.5cm pieces which represents significant size reduction 
from the previous design that measures 5cm x 5cm. 
To immobilize the aptamer molecules on the CNT surface, an activation layer was first 
created by pipetting a mixture of 0.4M 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(Geno Technology) and 0.1M N-hydroxysuccinimide (MP Biomedicals LLC) in 1:1 
volume ratio. The droplet was maintained for 3h at room temperature and cleaned with 
DI H2O wash and N2 dry. Subsequently, 0.1μM aptamer solution was pipetted on the 
surface-treated CNT and maintained for 24h at room temperature. The premature 
drying of the droplets for surface modifications was prevented by placing the sensors in 
a humidified chamber.  
 
2.3.3 Drug delivery device fabrication  
The drug delivery consists of three subcomponents: a top layer with a patterned gold 
electrode and suspended capping membrane, a bottom layer with a patterned gold 
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counter-electrode and custom packaging to hold the two layers and define a micro-
reservoir for vasopressin storage. Fabrication procedures for the top silicon structure 
are described in details in a previous publication (Chung et al., 2009). Briefly, silicon 
nitride was deposited on both sides of a silicon wafer using low pressure chemical 
vapor deposition (LPCVD) followed by gold deposition on the top and patterning for 
reservoir location on the bottom. The wafer was later immersed in potassium hydroxide 
(KOH) overnight and reactive ion etching was used to remove the silicon nitride in the 
patterned reservoir location, leaving a 100μm x 100μm gold capping membrane. 
Modifications in our new architecture regard the other two components of the device 
and serve to facilitate subcomponent fabrication and assembly. The replacement of a 
gold deposited Pyrex layer with a single gold electrode eliminates the standard lift-off 
processing before the gold deposition. Furthermore, the custom packaging is used in 
place of PDMS in order to facilitate assembly protocol and reduce leakage of 
vasopressin through the PDMS. The assembled components were sealed with epoxy 
adhesive. 
 
2.3.4 Power unit integration 
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A non-enzymatic glucose fuel cell unit, connected to a rechargeable battery, is 
used to power the microcontroller and other electrical components of the 
hemoAID. Lithium batteries were not used here since their short life-time makes 
them unsuitable for long term autonomous implantable devices with power 
requirements superior to that of pacemakers (Vincent, 2000). Non-enzymatic 
glucose fuel cells are promising power sources in such devices due to good long-
term stability and adequate power density. Here, we are using the stacked single 
layer configuration that we have presented previously (Oncescu and Erickson, 
2013) to demonstrate integration within the hemoAID. The 1cm2 single layer fuel 
cells are patterned directly on 500μm thick fused silica substrates. A Raney-type 
Pt/Ni alloy was used as anode for glucose oxidation and a Pt/Al alloy as cathode 
for oxygen reduction because of increased selectivity as discussed elsewhere 
(Kerzenmacher et al., 2008a; Oncescu and Erickson, 2011). The fuel cell unit is 
composed of 12 single layer fuel cells that are connected externally in parallel to 
form a fuel cell stack and integrated inside of custom holder with a volume of 
approximately 1cm3. 
 
2.4 Results and Discussion 
2.4.1 Integrated device operation in flow network 
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In order to demonstrate its operation, the hemoAID device was placed inside a 
closed chamber within a fluid network designed to simulate the physiological 
vasopressin states of late-phase HS patients. According to a clinical study by 
Jochberger et al. vasopressin concentration for patients with hemorrhagic shock 
rises from the normal 6±3pM range to 52±30pM as the body tries to reverse 
hypotension by releasing vasopressin (Jochberger et al., 2006). Following this 
initial increase, the level of vasopressin starts decreasing, which indicates the 
onset of late phase hemorrhagic shock. At that point, administering a high dose 
of vasopressin can temporarily stabilize the situation. Here, we demonstrate the 
operation of the hemoAID at those physiologically relevant vasopressin 
concentrations. The test chamber housing the integrated device (Fig. 2.2a) is 
initially filled with 100pM vasopressin solution, which corresponds to the high 
initial value (52±30pM) of blood vasopressin for patients prior to late-phase HS 
onset. The vasopressin concentration is then progressively lowered by 
introducing 10pM solution into the chamber using a VWR Mini-Pump at a flow-
rate of 0.115ml/s. The decrease in vasopressin concentration, indicating late-
phase HS, causes a decrease in resistance resulting in a voltage output drop 
across the nanowire sensor at constant current. This resistance drop across the 
sensor can be correlated to the vasopressin concentration. As shown in Fig. 2.2b, 
the sensor’s resistance decreased over 14min in response to the decrease in  
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Figure 2.2 Setup and experiment simulating vasopressin concentration changes 
in late-phase HS a) Setup for integrated device testing simulating late-phase HS 
b) resistance change, and associated vasopressin concentration change, detected 
by the biosensor during integrated experiment simulating late phase HS changes 
in vasopressin concentration. For the first 720s the vasopressin concentration is 
gradually lowered until the drug delivery is autonomously activated to 
counteract the drop in vasopressin (at 15% drop). The line at 720s shows the 
point at which drug delivery is activated. The inset shows the vasopressin drop 
before the drug delivery is activated (simulating the onset of late-phase HS)  
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vasopressin levels. Upon reaching a pre-determined 15% decrease in vasopressin 
concentration, corresponding to 0.25% resistance decrease ratio, the drug 
delivery is activated autonomously by the application of 35V between the top 
and bottom electrodes which results in the release of 16μL of highly concentrated 
(200μM) vasopressin. The localized vasopressin release was detected successfully 
by the sensor as can be seen in Fig. 2.2b. This temporary increase in vasopressin 
would allow a patient to survive until further medical assistance can be 
provided. The data obtained from the sensor is in the form of a voltage at the 
supplied current of 60mA. This can be transformed into a resistance change that 
is related to the vasopressin concentration change in solution via the following 
experimentally derived equation:  
Δ[VP] = 57.64 ΔR +102.68    (2.1) 
In the above equation Δ[VP] is in pM and ΔR is a % change in resistance. The 
relationship between changes in resistance and concentration is further discussed 
in the next section and is based on experiments presented elsewhere[20]. 
 
2.4.2 Biosensing ability of integrated device 
The nanowire biosensor we have developed and integrated in the hemoAID 
allows for the detection of pM changes in vasopressin concentration. 
Immobilized aptamer molecules on the nanowire biosensor act as electrical 
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bioreceptors for the surrounding vasopressin. Reversible vasopressin binding 
leads to changes in conductivity through the CNT detection zone. The sensor is 
based on a device developed previously with a limit of detection of 43pM in 
standard solution (He et al., 2013). In this section, we demonstrate the sensing 
ability of the hemoAID for gradual changes in vasopressin levels by performing 
several characterization experiments. First, we show the reversibility of our 
sensor’s detection mechanism by monitoring the sensor response to alternating 
vasopressin concentrations in a single experiment. The biosensor was placed into 
a custom packaging with micro-channels as shown in Fig. 2.3a and 0.01M 
Phosphate Buffer Saline (PBS) solution was introduced through one inlet until 
the output current was stabilized. The flow of 0.01M PBS was stopped after 20s 
and 10µM vasopressin was allowed to flow through the other inlet, which was 
again replaced by a PBS injection after another 30s. As shown in Fig. 2.3b, the 
initial introduction of a high-concentration 10µM vasopressin solution results in 
a current decrease, and resistance increase, through the sensor almost 
instantaneously which is a consequence of depletion of charge carriers on the 
CNTs due to vasopressin to aptamer binding. The recovery of current upon 
0.01M PBS injection at t=50s is due to the release of vasopressin molecules from 
the immobilized aptamer which demonstrates the reversible nature of the 
binding events. The slower rate of current change during the dilution is due to  
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Figure 2.3 Biosensor characterization a) Schematic of the nanowire biosensor 
and picture of the flow through system b) demonstration of sensor reversibility 
c) resistance, and associated current, change due to continuous decrease in 
vasopressin concentration in sheep serum. At t=0 sheep serum  with 100pM 
vasopressin is introduced, followed by 50pM, 10pM and with no additional 
vasopressin d) Percentage change in resistance from the initial no vasopressin 
case caused by the flow of sheep serum with different vasopressin concentrations 
(average of 5 experiments with the error bars representing the highest and lowest 
reading)   
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the low dissociation constant of aptamer-vasopressin complex, confirming the 
high affinity of aptamer molecules to vasopressin.(Maehashi et al., 2009) This 
experiment demonstrates the biosensor’s rapid reversibility even when a high 
vasopressin concentration causes large changes in resistance, uncommon under 
normal physiological conditions. In addition, we show that the sensor can be 
used to monitor physiologically relevant changes in serum vasopressin 
concentration. In Fig. 2.3c, the biosensor is subjected to continuous variations in 
vasopressin by flowing sheep serum (Valley Biomedical Inc.) with 100pM, 50pM, 
10pM and 0pM of added vasopressin in the respective order for a period of 150s 
at each concentration. With each dilution, the current through the sensor 
increases as expected due to the release of vasopressin from the immobilized 
aptamers. In Fig. 2.3d we show the percentage change in current from the initial 
no vasopressin case due to the addition of 10pM, 50pM and 100pM vasopressin. 
The bar graph represents the average of 5 experiments that were performed by 
continuously varying the concentration of vasopressin as shown in Fig. 2.3c, with 
the error bar representing the range between the highest and lowest reading. 
These experiments demonstrate that the sensor can detect physiologically 
relevant changes in vasopressin in serum.  
The high current used to increase the sensitivity of the sensor in the previous 
section can be decreased by changing the design of the sensor to increase its 
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resistance either by decreasing the thickness of the nanowire sensing area on 
which APTMS is immobilized or by integrating several such nanowires in series. 
With these improvements, the sensor can be used for detection of vasopressin in 
interstitial fluid where changes in vasopressin are gradual and not affected by 
pressure changes in the bloodstream. 
 
2.4.3 Stabilizing vasopressin levels through drug delivery 
In this section we demonstrate the integrated device’s mechanism to stabilize 
vasopressin levels through the in-parallel operation of the drug delivery system 
(Fig. 2.4a) with the biosensor. Time-controlled ejection of vasopressin based on 
electrochemical principles as shown in Fig. 2.4b has been demonstrated in 
previous publications (Chung et al., 2009; Cordovez et al., 2010). To release 
vasopressin, electrical potential is applied between the top and bottom electrodes 
which results in two distinct reactions. The first is the electrolytic reaction in the 
reservoir that causes gas bubble formation and pressure build-up as a result. The 
second is the reaction between the chlorine ions in the buffer solution and the 
gold capping membrane to form a water soluble complex that gradually 
dissolves until it ruptures with increasing pressure of the reservoir.  In the 
experiment presented in Fig. 2.4c, the sensor and the capping membrane of the 
drug delivery system were aligned 50mm apart using a custom holder and  
  29 
 
 
 
 
 
 
 
 
 
Figure 2.4 Electrochemical drug delivery device a) Assembly of the drug delivery unit 
b) vasopressin ejection over 25s of applied voltage c) increase in biosensor voltage due to 
drug delivery. The vertical dotted line indicates when the potential was applied (at t=0s) 
and the a sustained spike in voltage occurs after 25s  
  30 
immersed in a 0.01M PBS solution. After approximately 162s, the voltage output 
has stabilized (at t=0s on the graph), and the drug delivery was initiated by the 
application of a 35V potential between the top and bottom electrodes of the drug 
delivery system. The electrochemical ejection procedure has been imaged to 
suggests the onset of gold membrane rupture 5s after the potential application 
(Cordovez et al., 2010) and a sustained spike in voltage is first observed after 25s. 
The small magnitude of this signal (0.25mV) and the slow response of the sensor 
are due to large distance between the sensor and the drug delivery device. In the 
integrated hemoAID device, and the experiment in Fig. 2.4b the sensor is placed 
5mm in front of the sensor and the release of 16μL vasopressin solution at 200μM 
causes a much more rapid and larger voltage increase of 3.7%. This experiment 
demonstrates the ability of the sensor to monitor sudden changes in vasopressin 
concentration due to drug delivery by measuring the increase in voltage even 
when the two components are not in direct proximity.  
 
2.4.4 Powering of integrated device  
Instead of using the fuel cell unit directly to power the device, a small 
rechargeable battery shown in Fig. 2.5a is used as an intermediate in order to 
decrease power supply fluctuations. In addition this also allows excess energy to 
be stored and used for the one-time operation of the drug delivery device. 
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The power consumption for the integrated device with the sensor operated 
continuously is around 60mA at 3V. This is well above what can be supplied by a 
1cm3 fuel cell unit (20µA at 0.15V) however most of the power is required by the 
biosensor since the change in resistance across the detection area is directly 
proportional to the current applied. Although decreasing the current supply is in 
theory possible, this results in lower detection sensitivity. However, the 
microcontroller only requires 60 to 70A at 3V to operate and we can operate the 
sensor at discrete time intervals, thus greatly reducing the power consumption of 
the system and making it possible to operate the system using a 1cm3 fuel cell 
unit. In Fig. 2.5b we show the chronoamperometric response of the fuel cell unit 
(composed of 12 stacked single layers) at 0.1V in 0.01M PBS solution (pH 7.4) and 
physiological levels of glucose and oxygen (5mM glucose, 8% oxygen saturation) 
over a period of 10h. In Fig. 2.5c we show the discharge profile of the Thinergy 
MEC225 with an operating current of 100A. By continuously charging the 
Thinergy battery the system can operate continuously over a long period of time 
and avoid the power fluctuations typical of glucose fuel cell units (±4% as can be 
seen in Fig. 2.5b). 
 
2.5 Conclusion  
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 In this chapter, we have introduced the hemoAID, a device that can be used to 
detect a gradual drop in vasopressin concentration, corresponding to the onset of 
late-phase hemorrhagic shock, and deliver a highly concentrated dose of 
vasopressin to help stabilize the situation. We have demonstrated its operation in 
a controlled fluidic environment in which a 15% drop in vasopressin 
concentration was sensed and automatically triggered the activation of the drug 
delivery system. We discussed the sensor’s mechanism and ability to operate in a 
complex medium such as sheep serum thus opening the door to the development 
of an implantable device for late phase hemorrhagic shock prevention.  
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Figure 2.5 Power unit characterization a) Power unit consisting of a 1cm
3
 fuel cell unit 
in 5mmol glucose solution at 8% O2 saturation and an external rechargeable battery b) 
chronoamperometric response of the fuel cell unit at 0.1 V in 0.01 M PBS solution and 
5mmol/L glucose solution over a period of 10h c) discharge profile for the rechargeable 
battery at an operating current of 100µA  
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Chapter 3 
Microfabricated Enzyme-Free Glucose Fuel Cell 
for Powering Low-Power Implantable Devices1 
 
3.1 Abstract 
In the past decade the scientific community has showed considerable interest in 
the development of implantable medical devices such as muscle stimulators, 
neuroprosthetic devices, and biosensors. Those devices have low power 
requirements and can potentially be operated through fuel cells using reactants 
present in the body such as glucose and oxygen instead of non-rechargeable 
lithium batteries. In this chapter, we present a thin, enzyme-free fuel cell with 
high current density and good stability at a current density of 10 µA cmˉ². A non-
enzymatic approach is preferred because of higher long term stability. The fuel 
cell uses a stacked electrode design in order to achieve glucose and oxygen 
separation.  An important characteristic of the fuel cell is that it has no membrane 
separating the electrodes, which results in low ohmic losses and small fuel cell 
 
1 Oncescu, V., Erickson, D. "A Microfabricated Low Cost Enzyme-Free Glucose 
Fuel Cell for Powering Low-Power Implantable Devices" Journal of Power Sources 
196, 9169-9175 (2011) 
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 volume. In addition, it uses a porous carbon paper support for the anodic 
catalyst layer which reduces the amount of platinum or other noble metal 
catalysts required for fabricating high surface area electrodes with good 
reactivity. The peak power output of the fuel cell is approximately 2µW cmˉ² and 
has a sustainable power density of 1.5 µW cmˉ² at 10 µA cmˉ². An analysis on the 
effects of electrode thickness and inter electrode gap on the maximum power 
output of the fuel cell is also performed. 
 
3.2 Introduction  
The ability of different abiotic catalysts to catalyze oxygen and glucose reactions 
has been extensively studied. It was demonstrated that several catalysts such as 
silver and activated carbon can selectively catalyze oxygen reduction in the 
presence of glucose while platinum alloys such as platinum-bismuth can catalyze 
glucose oxidation in deaerated solutions. To date, no abiotic catalyst material has 
been found to selectively catalyze glucose oxidation in the presence of oxygen 
(Kerzenmacher et al., 2008a). In order to get around the catalyst selectivity issue, 
a stacked electrode approach has been used to achieve reactant separation 
(Kerzenmacher et al., 2011; Rao and Richter, 1974).  In this approach, a permeable 
cathode that selectively catalyzes oxygen reduction is placed in front of the 
anode, thus removing some of the oxygen from the solution before it defuses to 
the anode allowing glucose oxidation to proceed at low oxygen concentrations. 
Porous cathodes have been fabricated either by suspending the cathode catalyst 
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material in a hydro-gel and spreading the mixture onto a current conducting 
platinum mesh (Kerzenmacher et al., 2011) or by etching holes through a silicon 
cathode support before depositing the catalyst layer. Since the last approach 
doesn’t require a conducting platinum mesh, it is more suited for fabricating 
highly compact electrodes. In order to increase the surface area of the electrodes, 
several methods such as Raney type alloying and coating of the silicon wafers 
with carbon nanotubes have been used (Rao et al., 1976).   
In this chapter we demonstrate the advantage of fabricating the cathode using a 
thin platinum catalyst layer deposited on a carbon paper membrane. Since the 
carbon paper is conductive, porous, and has a high surface area, the platinum 
catalyst layer can be deposited directly on the membrane thus requiring less 
platinum catalyst and less intermediate steps in order to obtain a high surface 
area electrode.  Section 3.3 gives an overview of the theory behind abiotic glucose 
fuel cells and some important characteristics affecting performance for the 
stacked electrode design. Section 3.4 goes over the fabrication of the fuel cell 
presented in this chapter, section 3.5 describes the experimental setup and 
section 3.6 presents the experimental results.  
 
3.3 Abiotic glucose fuel cell theory and operation   
Glucose fuel cells produce electrical current through a proton coupled electron 
transfer (PCET) reaction where oxygen is reduced at the cathode and glucose is 
oxidized at the anode. Assuming glucose is oxidized to gluconic acid, the 
  37 
theoretical cell voltage of a fuel cell is 1.3V (Kerzenmacher et al., 2008a). The 
open circuit voltage is however much lower than that due to fuel and oxidant 
cross-over resulting in mixed potentials at both electrodes. Cross-over occurs 
when both fuel and oxidant react at the same electrode, a situation that is 
unavoidable in glucose fuel cells operating in-vivo where glucose and oxygen are 
hard to effectively separate before reaching the electrodes.  
The stacked electrode design takes advantage of the fact that the physiological 
concentration of glucose is two orders of magnitude higher than that of dissolved 
oxygen (Kerzenmacher et al., 2008a). Consequently most of the oxygen is 
reduced before crossing the porous cathode while only a small fraction of the 
glucose is oxidized. The glucose oxidation reaction can therefore proceed at the 
anode under low-oxygen conditions. In this manner, stacked electrode fuel cells 
can achieve good power output despite poor electrode selectivity. In order to 
reduce the amount of oxygen reaching the anode and competing with the 
glucose oxidation reaction, it is possible to increase the thickness of the cathode. 
However, we will show experimentally in section 3.6.4 that this also reduces the 
maximum power output of the full cell by decreasing glucose diffusion to the 
anode.  
When a small current is drawn from a fuel cell, the actual voltage is lower than 
the theoretical voltage due to activation losses. Activation losses depend on the 
nature of the catalyst and are significant in abiotic glucose fuel cells due to slow 
reaction kinetics at the electrodes. As the current is increased the cell voltage 
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drops linearly due to ohmic losses in the fuel cell caused by the relatively poor 
conductivity of the electrolyte. The resistance of the electrolyte is given by: 
      (3.1) 
where L is the distance between electrodes, σ is the electrical conductivity and A 
is the cross-sectional area of the electrolyte. From Eq. 3.1 it can be seen that 
increasing the gap between the electrodes increases the ohmic losses in the fuel 
cell. In addition, separating the electrodes by a porous filter membrane, as is 
commonly done, greatly decreases the electrolyte cross-sectional area and 
increases ohmic resistance (Kerzenmacher et al., 2011). In this chapter, we have 
assembled the fuel cell without a filter membrane in order to avoid this problem.    
Decreasing the inter-electrode gap also produces a higher glucose concentration 
gradient at the anode. The relationship between current density and the 
concentration gradient is given by: 
     𝑖/𝐴=(Co−Cb)/      (3.2) 
where i/A is the faradaic current density, n is the number of electrons transferred, 
F is the Faraday constant, D is the diffusion coefficient and (Co-Cb) is the 
difference between the concentration at the electrode surface and the bulk 
concentration over the Nernst diffusion layer thickness . Fig. 3.1 shows the 
main sources of voltage losses that occur in glucose fuel cells as well as the 
change in glucose concentration through the inter-electrode gap. 
 ALR /
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Figure 3.1 Stacked glucose fuel cell principle of operation. Stacked glucose fuel 
cell structure with cell resistance losses and glucose concentration profile in the 
inter-electrode gap 
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Despite the positive effects of reducing the distance between electrodes, it is 
shown experimentally in section 3.6.4 that the maximum power density actually 
decreases as the distance between electrodes decreases below a certain critical 
length. This occurs when inter-electrode gap length approaches the Nernst 
diffusion layer thickness and starts affecting the concentration gradient at the 
anode. Other issues affecting performance at small inter-electrode gaps include 
hydrogen bubble formation in the inter-electrode gap (Nagai, 2003) and 
accumulation of reaction products, such as gluconic acid and hydrogen ions, at 
the anode surface due to poor diffusivity through the membrane. The latter also 
affects the pH in the inter-electrode gap and has a large effect on the reaction 
rates at the electrodes.  
 
3.4 Fabrication  
3.4.1 Anode fabrication  
The steps for the anode microfabrication are shown in Fig. 3.2. A four inch silicon 
wafer was used as substrate for the catalyst layer deposition.  High surface area 
Raney type anodes for glucose oxidation are obtained by alloying platinum with 
nickel and subsequently extracting the unalloyed nickel. It was demonstrated 
(Rao et al., 1976)  that depending on the initial nickel to platinum ratio, such 
catalysts exhibit up to nine times higher current densities in deaerated phosphate  
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Figure 3.2 Anode and Cathode fabrication. Fabrication and assembly steps of 
the stacked electrode glucose fuel cell 
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buffer than conventional platinum black electrodes. E-beam evaporation (CHA 
Evaporator) was used to deposit 20nm of titanium in order to promote adhesion 
followed by 100nm of platinum and 300nm of nickel. The wafer was 
subsequently annealed for 2 hours in nitrogen gas at 500°C (MRL Industries 
Furnace). In order to avoid oxide formation when opening and closing the 
furnace door, the stand-by temperature of the furnace was kept below 300°C. The 
sheet conductivity of the wafer after each process step was measured using a 
CDE ResMap Resistivity 4 point Probe to ensure that no oxide layer would form 
at the surface and reduce the surface conductivity of the electrode. The wafers 
were then kept in 1:1 solution of sulfuric acid and nitric acid for 12 hours in order 
to ensure that all the unalloyed nickel has been removed. Upon removal, X-
ray photoelectron spectroscopy (XPS) analysis on the wafer was performed and 
it showed no traces of unalloyed nickel. The inter-electrode gap was patterned 
directly on the cathode using parylene for electrical insulation and SU-8 photo 
resist for setting the desired inter-electrode gap size. Approximately 2µm of 
parylene was deposited using a Parylene Coating System. The SU-8 photoresist 
was then spun and patterned directly on top of the parylene. The patterned 
wafer was later diced in 15mm by 15mm squares using a K&S 7100 Dicing Saw. 
The parylene was then etched in oxygen plasma through the SU-8 mask using a 
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Oxford PlasmaLab 80+ RIE System and the depth of the pattern was measured 
using a P-10 Profilometer tool.  
3.4.2 Cathode fabrication 
The cathode for oxygen reduction was fabricated by sputtering platinum directly 
onto a porous substrate. The porosity and structure of the support membrane has 
a strong effect on the amount of glucose and oxygen that passes through the 
cathode. Consequently several types of membranes were considered and two 
chamber diffusion experiments, not shown in this chapter, were performed in 
order to characterize the diffusion through those membranes. Based on these 
experiments, Teflon coated carbon paper (Toray TGP-H-090) and anodized 
aluminum oxide membranes (Whatman AAO) were selected. Scanning electron 
microscope (SEM) images of the two membranes are presented in Fig. 3.3. The 
carbon paper membrane is 300µm thick and has the advantage of being 
conductive and having a high surface area. The AAO membrane is non-
conductive and has a relatively small surface area but has the advantage of being 
only 60µm thick, which in principle allows for the fabrication of smaller more 
compact fuel cells with better glucose diffusion to the anode. The catalyst layer 
was obtained by directly sputtering 100nm of platinum onto each side of the 
porous membranes. Better platinum coverage inside the pores was obtained 
when the porous membranes were rotated during deposition.  Sections 3.6.1 to 
3.6.3 present experimental results for fuel cells assembled using a carbon paper  
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Figure 3.3 Assembled fuel cell. Assembled fuel cell and SEM images of (a) AAO 
membrane cathode, (b) carbon paper porous cathode and (c) platinum-nickel 
alloyed anode 
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supported cathode, while section 3.6.4 presents performance comparisons 
between fuel cells with carbon paper and AAO membrane supported cathodes.   
 
3.4.3 Fuel cell assembly  
Copper wires (28 Gauge L.J Leahy) were bonded to the electrodes using silver 
epoxy (M.G. Chemicals). The electrodes were then held together in a specially 
designed 3D printed holder and epoxy (Hardman Double Bubble Epoxy) was 
used to seal the two parts of the holder together. Fig. 3.3 shows an assembled 
fuel cell mounted on a glass slide as well as scanning electron microscope SEM 
images of the anode and cathode surfaces.  
 
3.5 Experimental setup and procedure  
3.5.1 Fuel cell testing environment  
All experiments were carried out under controlled conditions at physiological 
levels of glucose (5.0 mmol Lˉ¹) and dissolved oxygen (7% saturation) in 0.01M 
phosphate buffer saline (pH 7.4) at 37oC using a setup similar to the one 
described by Kerzenmacher et al (Kerzenmacher et al., 2011) and presented here 
in Fig. 3.4a. Two flow meters (VWR 20–200 SCFM) were used to adjust the ratio 
of air and nitrogen (Airgas NI-200) flowing in the solution.  In order to have a 
more stable environment and to minimize rapid changes in oxygen 
concentrations, the testing chamber was divided in two parts: one where the fuel  
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Figure 3.4 Experimental setup (a) Controlled experiment set-up for fuel cell testing (b) 
Electrical testing set-up 
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cells are kept and one where the nitrogen and glucose are introduced. A porous 
membrane separated the two compartments of the testing chamber. Up to four 
different fuel cells were tested simultaneously using this setup. A dissolved 
oxygen meter was used to continuously monitor the oxygen levels and 
temperature. A Silver-Silver chloride reference (Aldrich Double junction 
Ag/AgCl reference) electrode was used as the reference against which electrode 
potentials were measured. 
 
3.5.2 Electrical testing setup  
As illustrated in Fig. 3.4b, a Keithley 2400 Source-meter was used to apply a 
current sweep across the fuel cells and a Keithley 2000 Multi-meter equipped 
with a scanner card was used to take the voltage measurements of individual 
electrode potentials versus the reference electrode. The current sweep and 
channel switching was remotely controlled using a LABVIEW program. All 
current- potential characterization experiments were performed at a low sweep 
rate of 9 µA hˉ¹ in order to ensure that the readings were taken at a stable 
potential.  
 
3.6 Experimental results  
3.6.1 Electrode characterization experiments 
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Characterizing the individual performance of the cathode prior to integration in 
the fuel cell was carried out using a 3 electrode setup with a silver-silver chloride 
reference electrode and a carbon-paper auxiliary electrode. The potential versus 
current curves are shown in Fig. 3.5a for both the platinum on carbon paper 
electrode and the carbon paper electrode. A positive potential indicates that there 
is a cathodic current and that the oxygen reduction occurs as expected at the 
working electrode.  It can be seen that the platinum on carbon paper electrode 
shows much better oxygen reduction potential than the carbon paper alone. The 
platinum on carbon paper electrode was prepared as described in section 3.2 by 
sputtering 100nm of Pt on both sides of the carbon paper. Preliminary 
experiments, not shown in this chapter, with a higher amount of sputtered 
platinum on the carbon paper did not result in higher cathodic current, 
indicating that 100nm is enough to fully coat the carbon paper with a catalyst 
layer.  In addition, the open circuit voltage (OCV) of the electrode Platinum- 
Nickel electrodes against the Ag-AgCl reference electrode at different oxygen 
partial pressures is presented in Fig. 3.5b. It can be seen that due to the high 
reactivity of oxygen at the platinum surface, the OCV increases rapidly between 
0% and 1% oxygen saturation. This demonstrates the necessity of fabricating the 
cathode in a way that minimizes the access of the oxygen to the anode.  
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Figure 3.5 Electrode characterization (a) Potential versus current density plot for 
carbon paper (CP) and platinum on carbon paper (Pt/CP) cathodes (b) Effect of 
oxygen partial pressure on Pt/Ni electrode potential  
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3.6.2 Overall fuel cell performance  
The overall performance of the glucose fuel cell with carbon paper supported 
cathode was characterized using the setup described in section 3.4.4.  Fig. 3.6a 
shows the cell potential and power density versus current density. The median 
value of three different experiments is indicated by the symbol and the error bars 
indicate the maximum and minimum experimental value. The peak power 
output for the cell is just under 2 μWcmˉ² and occurs at a current density of 15 
μA cmˉ². Although the peak power output is lower than what has been reported 
elsewhere for mesh-free stacked fuel cells, the current density is much higher 
indicating better electrode kinetics. In addition, the fuel cell presented in this 
chapter uses only 300nm of platinum catalyst, over 100 times less than previous 
mesh-free designs, making it a relatively low-cost power source with a power 
density high enough for powering implantable sensor devices. Fig. 3.6b shows 
the power density of a fuel cell at a constant current density of 10 µA cmˉ² over a 
period of 4 hours. A large initial drop in power density is observed due to the 
slow load change response of the fuel cell, however after a few minutes a stable 
power density of about 1.5 µW cmˉ² is reached. A power drop of less than 0.2 µW 
cmˉ² is observed over the next 4 hours demonstrating that the carbon paper 
supported fuel cell is relatively stable at large current densities. The stable power 
density of  1.5 µW cmˉ² at 10 µA cmˉ² is consistent with the data presented for the  
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 Figure 3.6 Overall fuel cell performance (a) Dependence of cell voltage and power 
density on current density (b) Cell Voltage versus time at 10µW over a period of 4h   
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polarization curve in Fig. 3.6a demonstrating that a sweep rate of 9 µA hˉ¹ did 
not lead to an overestimation of the performance. 
 
3.6.3 Effect of inter-electrode gap and cathode thickness  
The fuel cell presented in the previous sections had an inter-electrode gap size of 
160 µm and a cathode thickness of 300 µm. As described in section 2, it is 
expected that the gap between the electrodes to be an important factor 
determining fuel cell performance. In order to see the effect of the inter electrode 
gap on the maximum power output of the fuel cell, different gap thicknesses 
(50µm, 100µm, 160µm and 260µm) were patterned directly on the anode using 
SU-8 photoresist. The gap pattern was fabricated using standard 
photolithography techniques as described in section 3 and the height of the 
pattern was measured using a P-10 Profilometer tool.  Three fuel cells of each gap 
size were assembled and tested and the results are presented in Fig 3.7a. It can be 
seen that the 160µm gap electrode gave the maximum power density of 2 
µWcmˉ². As mentioned is section 2, the decrease in performance can be 
attributed to the change in concentration gradient at the anode as the gap size 
approaches the Nernst diffusion layer thickness. However, other effects such as 
hydrogen bubble formation at the anode and accumulation of reaction products 
at the electrode surface due to poor diffusivity through the membrane can also 
contribute to these observations.  
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Figure 3.7 Fuel cell optimization (a) Effect of inter-electrode gap and (b) effect of 
electrode thickness on maximum power density  
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The effect on cathode thickness on maximum power output is presented in Fig. 
3.7b. The carbon paper used as a support for the platinum catalyst is 0.3mm 
thick. Different cathode thicknesses were obtained by stacking 2 and 3 platinum 
on carbon paper electrodes and binding them with silver epoxy. Results indicate 
that a double stacked cathode performs better than the single electrode one but a 
sharp decrease in performance occurs for the triple stacked cathode. Although 
more oxygen reacts at the cathode when the thickness is increased, the diffusion 
of glucose to the anode appears to become the limiting factor. 
 
3.6.4 Comparison between different cathode supports  
The performance of fuel cells with the cathode fabricated by sputtering platinum 
directly on a anodize aluminum oxide membrane was also measured. Fig. 3.8 
shows the difference in power output between the two. It shows that everything 
else being identical during the fabrication, the carbon paper support gives a 
much better performance. The large difference in performance between the two 
can be explained by the much smaller cathode surface area obtained when a 
AAO membrane is used as cathode support. In addition, given that the 
membrane has a thickness of only 60µm, compared to 300µm for the carbon 
paper, it allows a larger amount of oxygen to diffuse through resulting in mixed-
potential at the anode. 
 
  55 
 
 
 
 
 
Figure 3.8 Effect of different cathode support layers.  Comparison between 
carbon paper (CP) and anodized aluminum oxide (AAO) cathode supports on 
fuel cell power output 
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3.7 Conclusions 
In this chapter we have demonstrated the possibility of micro- manufacturing 
enzyme-free glucose fuel cells without a filter membrane between the electrodes. 
This results in stacked fuel cells with lower ohmic resistance and better glucose 
diffusion to the anode. Compared to other designs the current fuel cell achieves 
much higher current densities. We also demonstrate the advantage of using a 
conductive support such as carbon paper since it reduces the amount of 
platinum required for producing high surface area electrodes. The performance 
of platinum on carbon paper supported electrodes is much better than that of 
electrodes produced in a similar manner on anodized aluminum oxide 
membranes because of the higher surface area of the carbon paper. In previous 
studies, in order to fabricate the cathode, either a hydrogel was used to support 
the catalyst materials (Kerzenmacher and Sumbharaju, 2007) or a silicon wafer 
with etched holes was used as a substrate for the deposition of the cathodic 
layer(Kerzenmacher et al., 2011). The first method has the drawback of 
producing thick electrodes and having limited stability against hydrolytic and 
oxidative attack while the latter approach requires numerous fabrication steps 
and a thick platinum catalyst layer for the formation of a high surface area Raney 
type catalyst layer. The carbon paper support allows for the fabrication of thinner 
and more stable electrodes which results in better glucose diffusivity through the 
cathode as indicated by the higher power density. It was shown that a peak 
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power density of 2 µW cmˉ² occurs when the inter-electrode spacing is about 
160µm. At large inter-elecrode spacing the peak power density is lower due to 
higher ohmic losses, while at smaller inter-electrode spacing the decrease in 
performance can be attributed to the change in concentration gradient at the 
anode as the gap size approaches the Nernst diffusion layer thickness. A small 
increase in performance was observed as the cathode thickness was increased 
from 300µm to 600µm but a sharp decrease was observed as the thickness was 
further increased. This shows that although a thicker electrode allows for better 
oxygen-glucose separation, the decrease in diffusivity of glucose to the anode 
becomes the limiting factor. 
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Chapter 4 
High volumetric power density, non-enzymatic, 
glucose fuel cells1  
 
4.1 Abstract  
The development of new implantable medical devices has been limited in the 
past by slow advances in lithium battery technology. Non-enzymatic glucose fuel 
cells are promising replacement candidates for lithium batteries because of good 
long-term stability and adequate power density.  The devices developed to date 
however use an “oxygen depletion design” whereby the electrodes are stacked 
on top of each other leading to low volumetric power density and complicated 
fabrication protocols. Here we have developed a novel single-layer fuel cell with 
good performance (2µW cm-2) and stability that can be integrated directly as a 
coating layer on large implantable devices, or stacked to obtain a high volumetric 
power density (over 16µW cm-3).  This represents the first demonstration of a low 
volume non-enzymatic fuel cell stack with high power density, greatly increasing 
the range of applications for non-enzymatic glucose fuel cells. 
 
1 Oncescu, V., Erickson D. "High volumetric power density, non-enzymatic, 
glucose fuel cells." Scientific Reports 3 (2013) 
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4.2 Introduction  
Non-rechargeable lithium batteries have been successfully used in implantable 
medical devices for over 40 years, however their life cycle is often much shorter 
than the desired period of implantation for such devices (Vincent, 2000). For 
example, over 20% of the 200,000 annual pacemaker implants in the United 
States are performed in order to replace depleted batteries, whose lifetimes are 
limited to 5 to 7 years (Kurtz et al., 2010). This results in unnecessary infection 
risks, inconvenience to patients, and billions of dollars in costs to the health care 
system. In addition, due to advances in biosensors and low-power electronics, a 
host of new implantable systems such as pacing devices to prevent congestive 
heart failure, cochlear implants to treat profound deafness, and deep brain 
simulators to treat symptoms of Parkinson’s disease have been proposed 
(Schmidt and Skarstad, 2001). Because such devices have higher power 
requirements than pacemakers and have a very short lifetimes when powered by 
current batteries (Wei and Grill, 2009), researchers are developing new 
implantable power sources that can harvest chemical, thermal and mechanical 
energy from the human body as an alternative to lithium batteries (Heller, 2006; 
Wei and Liu, 2008). These include piezoelectric (Khaligh et al., 2010; Qi and 
McAlpine, 2010) and thermal generators (Stark, 2006) and bio-fuel cells(Heller, 
  60 
2004; Schröder, 2012). Glucose fuel cells are particularly interesting because of 
the abundance of oxygen and glucose in body tissue and the possibility to 
generate a stable high continuous power output through the coupling of the 
glucose oxidation and oxygen reduction reaction (Kerzenmacher et al., 2008a). In 
the past few decades most research in the field has been focused on 
immobilization methods for enzymatic catalysts in an effort to increase the 
lifetime of glucose fuel cells (Moehlenbrock and Minteer, 2008). Enzymatic 
catalysts for glucose/O2 fuel cells have excellent selectivity and can produce 
power densities of the order of several mWcm-2 however they have very short 
lifetime, typically less than 30 days, due to the fragile nature of the enzymes and 
poor immobilization techniques (Cinquin et al., 2010; Rengaraj et al., 2011).  This 
makes them generally unsuitable for long-term implantable applications (Kim et 
al., 2006) despite having been successfully tested in-vivo (Halámková et al., 2012; 
Szczupak et al., 2012; Zebda et al., 2011). 
Recently, there has been renewed interest in non-enzymatic fuel cells that use 
platinum alloys or activated carbon as catalysts (Kerzenmacher et al., 2008a). 
Such fuel cells have shown good time stability and have been successfully tested 
in-vivo (Drake et al., 1970; Sharma et al., 2011). The biggest challenge however 
remains the poor anode selectivity towards glucose oxidation in the presence of 
oxygen. Due to the lack of abiotic catalysts to selectively catalyze glucose 
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oxidation, several groups have developed fuel cell designs that reduce the access 
of oxygen to the anode.  An oxygen depletion design that has been commonly 
used involves placing a porous cathode in front of the anode such that most of 
the oxygen gets reduced prior to reaching the anode allowing glucose oxidation 
to proceed at low oxygen concentrations. The design first presented by Rao et al. 
in the 1970s made used of hydrogels to separate the porous anode and cathode 
(Rao et al., 1976). Kerzenmacher et al also used hydrogels as binder for the 
catalytic materials at the anode and cathode (Kerzenmacher et al., 2008b). More 
recent designs however have avoided the use of hydrogels and instead used 
porous membranes such as carbon paper or anodized aluminum membranes, as 
supports for the cathode catalyst.  In a previous paper, we demonstrated that 
such fuel cells can be assembled without a separation membrane in order to 
improve glucose diffusion to the anode and reduce the thickness of the fuel cell 
(Oncescu and Erickson, 2011). Although a promising approach, such oxygen 
depletion designs still require a large volume due to the thickness of each 
stacked electrode and the inter-electrode space, in addition to complicated 
fabrication and assembly protocols. The power density for such fuel cells is 
commonly reported in terms of electrode surface area exposed to interstitial fluid 
instead of volume as is often the case for other power sources. For example, most 
depletion design fuel cells described in literature have in-vitro power densities 
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ranging from 2µWcm-2 to 4.4 µWcm-2, however the assembled devices require 
volumes of over 2 cm3 because of the need to hold the stacked electrodes together 
(Kerzenmacher et al., 2011). This results in volumetric power fuel cell densities of 
less than 2 µWcm-3, which makes them inefficient compared to piezoelectric and 
thermal generators that have fundamental power density limits of 30 µWcm-³ 
and10 µWcm-³ (Mitcheson, 2010) respectively. In order to address the issue, 
Kloke et al. has recently investigated a single layer design for glucose fuel cells by 
placing the anode and cathode side by side (Kloke et al., 2011). As noted there, a 
single layer design is desirable because of simplified fabrication, reduced 
thickness and facilitated implementation of the fuel cell in implantable devices. 
Although it was demonstrated that such single layer fuel cells can produce 
excellent power output (2.2 μW cm–2), their fabrication required over 50μm 
platinum sheets and no attempt was made at integrating them in high power 
density fuel cell units.   
Here we demonstrate how the single layer design can be manufactured cost-
efficiently on single wafers using standard fabrication protocols and integrated 
in both high surface area and low volume implantable devices. We start by 
presenting the fabrication protocol for the low-platinum single layer fuel cell 
(SLFC), followed by polarization curves for both electrodes in order to 
understand the limiting reactions and the effect of changes in reactant 
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concentration on fuel cell performance. We then demonstrate how SLFCs can be 
designed to reduce mixed potential effects when used as coating layers for 
implantable devices. Finally we show how we can stack SLFCs to produce high 
power density fuel cell units. 
 
4.3 Results  
4.3.1 SLFC fabrication and characterization  
The single-layer fuel cells (SLFCs) developed here are patterned directly on 
500μm thick fused silica substrates (Fig. 4.1a) and subsequently diced to obtain 
1cm2 fuel cell layers. A concentric design where the anode is surrounded by the 
cathode was selected because, as will become apparent in the next sections, it 
increases the interface area between the electrodes and it helps increase glucose-
oxygen separation when the layers are stacked. In order to achieve high effective 
surface area, a Raney-type alloy process is used for both the anode and the 
cathode. This process, first demonstrated by Gebhardt et al., involves the 
annealing of a thin layer of platinum with a non-noble metal followed by the 
chemical etching of the non-alloyed outer metal layer. In this chapter nickel is 
used as the non-noble metal at the anode and aluminum at the cathode (Rao et 
al., 1976). We use a Ni/Pt alloy as anode for glucose oxidation because it has 
been shown elsewhere to exhibit greater selectivity towards glucose than other 
abiotic  
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Figure 4.1 Single layer fuel cell devices. (a) fused silica substrate before dicing 
with single layer fuel cells (SLFC) patterned on both sides (b) a typical device 
used in this work with leads attached (c) scanning electron microscopic (SEM) 
images showing the high surface area Raney-alloy structure of the anode at 
different alloying temperatures and at the cathode.   
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catalysts (Kerzenmacher et al., 2008a). The electrodes in the SLFCs presented 
here use only 100nm of platinum, significantly less than in other works where 
metals such as zinc or nickel were electroplated on 50μm thick platinum foils 
(Kerzenmacher et al., 2010b; Kloke et al., 2011). The main issue with using such 
thin layers of platinum is that the electrode roughness that can be obtained using 
a Raney process is significantly lower resulting is smaller electrode surface area. 
Experiments with several anneal temperatures in the range 400°C -600°C have 
demonstrated that the roughness that can be obtained using a Raney-type 
process in the case of 100nm Pt / 300nm Ni peaks when the annealing 
temperature reaches 500°C. For the cathode, a high surface area platinum surface 
was obtained by annealing 100nm Pt/ 100nm Al at a low-temperature of 300°C 
and subsequently etching the aluminum with NaOH. X-ray photoelectron 
spectroscopy (XPS) analysis was used to determine the metal composition at the 
anode surface before and after etching to ensure that no un-alloyed nickel was 
left behind. The roughness of the electrodes is apparent from scanning electrode 
microscopic (SEM) images (Fig. 4.1c) and has been quantified using a cyclic 
voltammetry method. By estimating the charge under the hydrogen adsorption 
peaks in the cyclic voltammograms during cleaning of the samples, the 
roughness factor (RF) of the Raney-type Ni/Pt anode annealed at 500°C was 
determined to be 238±15. This is significantly higher than the RF of commercially 
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available platinum foils (30±4) but an order of magnitude lower than the RF 
values reported by Gebhardt et al. for 50μm thick Ni/Pt Raney films (RF~2000)30. 
 
4.3.2 SLFC electrode characterization  
The polarization curves of the anode and cathode in SLFCs provide useful 
information as to the limiting reactions of the fuel cell and the effect of variations 
in glucose and oxygen concentration. Fig. 4.2a shows the polarization curves for 
the Pt/Al cathode at different oxygen and glucose concentrations. Two flow 
meters (0.2–2 SCFH) were used to adjust the ratio of air and nitrogen flowing in 
the 0.1M PBS solution and the temperature was maintained at 37°C. It can be 
seen that at low oxygen concentrations (7% O2 saturation) there are two distinct 
regions to the polarization curve, a linear ohmic region from 0 to 10 µAcm-2 and a 
transport-limited region above 10 µAcm-2. In the linear ohmic region the drop in 
voltage is due mainly to resistance in the electrolyte while in the transport-
limited region the voltage drop is due to low oxygen concentration near the 
electrode surface. At high oxygen concentration (21% O2 saturation) no transport 
limited-region is observed under 30µAcm-2. The effect of glucose on the cathode 
is relatively small with voltage drops of less than 20mV at current densities in the 
range 0 to 30µAcm-2 indicating that the Pt/Al alloy selectively catalyzes oxygen 
reduction in the presence of glucose. The electrode specific resistance in the  
  67 
 
 
 
 
Figure 4.2 Electrode polarization curves. (a) cathode i-V curves  showing the 
effect of 5mM glucose in solution and the effect of low oxygen partial pressure 
(7% oxygen saturation) (b) anode i-V curves at high (21% saturation) and low 
(2% oxygen saturation) oxygen partial pressure. The results represent the 
average of 3 measurements.              
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linear regime is given by R= ΔU/Δj=6.69 kΩcm-2. The cathode open circuit 
potential versus the Ag/AgCl reference electrode is comparable to what was 
previously reported by Kerzenmacher et al. for Raney-type Pt/Al alloys 
(Kerzenmacher et al., 2010a).  
For the Pt/Ni anode the polarization curves in Fig. 4.2b show that the potential is 
significantly lowered by the presence of oxygen, however because glucose is 
present in high concentrations in interstitial fluid, there is no transport limited 
region in the 0 to 30µAcm-2 range. The electrode specific resistance increases 
from 1.31 kΩcm-2 when only nitrogen flows in solution (2% O2 saturation) to 3.21 
kΩcm-2 when only air flows in solution (21% O2 saturation). The polarization 
curves presented in this section indicate that in a SLFC the polarization of the cell 
voltage is dominated by resistance at the cathode even when the oxygen partial 
pressure is above physiological levels. It can also be seen that a decrease in 
oxygen has a mixed effect on the polarization curve of the fuel cell since it 
decreases the resistance at the anode but creates mass transport limited effects at 
the cathode.   
 
4.3.3 SLFCs as coating layers to implantable devices   
SLFCs are attractive because they can be integrated directly as coating layers for 
implantable devices. However, as the polarization curve for the anode indicates, 
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the presence of oxygen can significantly reduce the performance of the anode. In 
addition, we observed from electrode polarization curves that for the cathode at 
low oxygen partial pressure there is a limiting current density above which the 
oxygen reduction reaction becomes transport limited. To address this, we have 
developed several designs that minimize these oxygen and transport limiting 
effects. First we look at the effect of varying the cathode to anode area ratio 
(denoted as n = Acathode/Aanode) in order to determine the optimal configuration 
such that the fuel cell is not limited by oxygen transport at the cathode. From Fig. 
4.3a we observe that at high oxygen partial pressures the maximum current 
density drawn from the fuel cell increases with increasing n. A peak power 
output of 1.21µWcm-2 is observed for SLFCs with n=3.7, a 50% increase over 
SLFCs with n=0.47, indicating that it’s beneficial to have a larger cathode surface 
area. This is expected since, as mentioned in the previous section, the 
polarization of the cell voltage is mainly driven by resistance at the cathode. In 
addition, at low oxygen partial pressure we expect the advantage of a lager 
cathode area to be even more accentuated due to higher electrode specific 
resistance at the cathode in the transport-limited regime.  
Using a similar approach to the above, we can also demonstrate how SLFC 
designs with high interface area between the electrodes can minimize mixed 
potential effects at the anode and improve the performance of the fuel cell. We  
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Figure 4.3 SLFC as coating layers (a) SLFCs used to test the effect n 
=Acathode/Aanode on fuel cell performance (here for SLFC A1 n=3.7, SLFC A2 n=1.39, 
SLFC A3 n=0.47)  (b) interdigital electrode fuel cells used to test the effect of 
interface area and oxygen concentration on fuel cell performance. The results 
represent the average of 3 measurements.              
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achieve this by having an interdigital interface, or comb-like interface, between 
the anode and the cathode as can be seen in Fig. 4.3b. Interdigital electrodes have 
been demonstrated before for electrochemical sensors (Van Gerwen et al., 1998), 
however our approach is the first implementation for non-enzymatic glucose fuel 
cells. Here the electrodes are separated by 500µm and the aim of the electrode 
pattern is to increase the area of oxygen depletion over the anode and decrease 
the ohmic resistance between the electrodes.  Since oxygen consumption is 
proportional to the current drawn from the fuel cell, the effect of oxygen 
depletion at the anode gets more significant when the fuel cell operates at high 
current densities.  Fig. 4.3b shows that the interdigital designs increases the peak 
power output of the SLFC from 1.05 µWcm-2 to just over 1.32 µWcm-2. The 
reported peak power output represents the average of 3 different experiments 
with sample standard deviation of ±0.09 µWcm-2 for the interdigital design and 
±0.12 µWcm-2 the non-interdigital design. The experiments described above were 
performed at high oxygen partial pressure (21% oxygen saturation) in order to 
avoid any experimental errors due to the flow of nitrogen in solution which is 
hard to control accurately. In another experiment, we lowered the oxygen 
concentration by increasing the flow of nitrogen in solution (7% oxygen 
saturation) and observed a large increase in power output for both interdigital 
and non-interdigital designs. This trend is consistent with our observations from 
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the anode polarization curves that predict a decrease in anode potential at lower 
oxygen concentrations. A similar increase in fuel cell performance was observed 
by Sharma et al when the fuel cells were tested in-vivo at lower oxygen partial 
pressure (Sharma et al., 2011). As shown in Fig. 4.3b the interdigital SLFC has a 
peak performance of approximately 2.01µWcm-2 at low oxygen partial pressure, 
compared to 1.36µWcm-2 for the non-interdigital SLFC. The improvement in 
peak power output is more significant in the interdigital case (52.3% increase 
compared to 29.3%) likely due to increased oxygen depletion over the anode. As 
was previously reported, a change in oxygen concentration at the anode surface 
has greater effect on fuel cell performance at lower oxygen partial pressures 
(Oncescu and Erickson, 2011). The peak power changes in this experiment are 
therefore consistent with that observation.  In addition, the reduced ionic 
resistance between the anode and the cathode due to the high interface area also 
contributes to the increased performance of the interdigital design. 
 
4.3.4 SLFCs in stacked configuration  
The greatest advantage of SLFCs over other non-enzymatic glucose fuel cells 
designs is that they can be integrated in very compact fuel cell units for volume 
sensitive implantable devices. As discussed previously, the glucose fuel cells 
developed so far have been intended to be used as coating layers for implantable 
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devices since their thickness and complicated stacked design makes them 
unsuitable for low volume applications. The SLFCs developed here, not only can 
be easily stacked, but doing so greatly increases their performance. Stacking the 
SLFC can reduce the amount of oxygen reaching the anode, as illustrated in Fig. 
4.4a, because only a small volume of interstitial fluid is allowed to diffuse 
through the sides and between the fuel cell layers.  Fig. 4.4b shows the effect of 
stacking on the overall performance of a SLFC. The gap δ between the SLFCs 
determines the amount of reactants that that can diffuse through the sides of the 
stacked fuel cell unit and over the electrodes. Using this approach some of the 
oxygen in solution reacts at the cathode before it diffuses to the anode allowing 
glucose oxidation to proceed at low oxygen concentrations as illustrated in Fig. 
4.4a. As discussed previously, some of the glucose reacts at the Pt/Al cathode, 
however the effect on the stacked SLFC’s performance is small because of the 
large difference in oxygen and glucose physiological concentration. In interstitial 
tissue, the glucose concentration is approximately 5 mmol L-¹ while that of 
oxygen is less than 0.2 mmol L-¹.  Decreasing the gap δ between the fuel cell 
layers can increase the peak power output of the SLFC. It can be seen in Fig. 4.4b 
that the increase can result in over 2 fold increase in power output per SLFC over 
the case where there is no stacking. For a SLFC A1 type fuel cell, a peak power  
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Figure 4.4 SLFC in stacked configuration (a) illustration demonstrating how 
confining the reactants diffusion can reduce the amount of oxygen at the anode 
(b) confined diffusion effect on fuel cell performance showing the increase in 
SLFC A1 performance when there is plate 0.5mm above the SLFC. The results 
represent the average of 3 measurements.               
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output of 1.88μW/cm² is obtained when δ is 0.5 mm. Although the fuel cell layers 
could potentially be stacked event closer together (δ≤0.5mm), this is not easily 
achievable for the current design, because of the thickness of the wires that were 
used as electrode connections. The experiments were performed at 37° in 0.1M 
PBS solution with physiological levels of glucose (5 mmol L-¹) and dissolved 
oxygen in solution (0.2 mmol L-¹).  
 
4.3.5 Integrated fuel cell unit  
In order to demonstrate the potential of SLFCs to be integrated in implantable 
devices as highly compact power sources we have assembled a fuel cell unit with 
stacked SLFCs connected externally in parallel. The holder was printed using a 
3D printer. The assembled device in Fig. 4.5a has a volume of approximately 
1cm3 and can accommodate 12 SLFCs printed on both sides of 1cm by 1cm diced 
pieces of 500μm thick fused silica wafers. That represents 12cm2 of fuel cell 
surface area exposed to solution. For comparison purposes an oxygen depletion 
design type fuel cell that we have previously developed(Oncescu and Erickson, 
2011) had a thickness of 0.5cm, a total volume of 2 cm3 and a surface area of 1cm2 
exposed to solution. The fuel cell had a power output of 2 μWcm-2 corresponding 
to a volumetric power output of roughly 1μWcm-3. Fig. 4.5b shows the cell  
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Figure 4.5 Confined Diffusion effect on performance (a) picture of one double 
sided SLFC along with a stack of 12SLFCs (b)  performance of the 12 SLFCs stack 
connected in parallel (c) chronoamperometric response at 0.1V in 0.01M PBS 
solution for the first 2h and after the addition of 5×10-3molL-1 glucose. 
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potential and power density versus current density for the stacked fuel cell unit 
in Fig. 4.5a. It can be seen that the peak volumetric power output is 16μWcm-3 
roughly 16 times higher than for the depletion design type fuel cell. The sweep 
rate used here is 18μA h-1. The performance is lower than the expected peak 
performance of 12 SLFCs connected in parallel, because of resistance losses in 
external SLFC connections.   
Chronoamperometric experiments were also performed to demonstrate the long-
term stability of the fuel cell unit. Fig. 4.5c shows the chronoamperometric 
response at 100mV over a period of 12 hours. For the first 2 hours the fuel cells 
was kept in 0.01M PBS solution after which 5mM glucose was added to the 
solution. It can be seen that a stable current output of 123μA was obtained 
following the addition of glucose and less than ±10% fluctuation was observed 
during the entire period. In addition, this stable current output at 100mV is 
consistent with the data presented for the polarization curve in Fig. 4.5b 
demonstrating that a sweep rate of 18μA h-1did not lead to an overestimation of 
the performance 
 
4.4 Discussion 
The results presented in this chapter demonstrate the potential of SLFCs to be 
integrated as high-performance low-cost glucose power sources in implantable 
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devices. Unlike other non-enzymatic fuel cells proposed previously, the SLFCs 
are thin and easy to fabricate and assembled using standard semiconductor 
processing technology. In addition, each electrode is fabricated using 100nm 
evaporated platinum, which is significantly less than in other designs where 
50μm thick platinum foils were used for fabricating Raney-type Pt/Zn alloys 
(Kerzenmacher et al., 2010b). Here, it was demonstrated that an inter-digital type 
SLFC can achieve up to 2.01μWcm-2 peak power output at physiological levels of 
glucose and oxygen and that a stacked fuel cell unit of 12 SLFCs can provide a 
volumetric power output of at least 16μWcm-3. It is important to note that here 
the performance is measured in terms of SLFC area which includes both 
patterned electrodes. The state-of-the-art depletion design fuel cells quote a 
power output of 2 to 4.4 µWcm-2 per area exposed to the solution, which is just 
the geometrical surface area of the cathode (Kerzenmacher et al., 2008b; Oncescu 
and Erickson, 2011) and does not take into account the thickness of the 
assembled fuel cell. In depletion design fuel cells the cathode is placed on top of 
the anode resulting in complicated assembly which makes them unsuitable for 
stacking and low volume applications. This makes such fuel cells hard to 
compare on volumetric power output basis with the SLFCs presented in this 
chapter. The single layer fuel cell presented by Kloke et al. has a peak power 
output of 2.2 μW cm–2 however it is not fabricated on a single substrate and has 
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not been  integrated in high power density fuel cell units as is the case in this 
chapter (Kloke et al., 2011).  The performance of the SLFCs can be improved 
further by developing more selective anodic catalysts (Kerzenmacher et al., 
2008a) or by increasing the surface area of the electrodes in the current design. 
Kloke et al. has recently demonstrated that a Raney-type platinum zinc catalyst 
obtained from 50μm thick platinum foils and 30μm thick layer of zinc can have 
an open circuit voltage of -400mV, significantly lower than the anode we 
presented here (Kloke et al., 2011). In addition surface area of the electrodes can 
be increased by immobilizing carbon nanotubes onto the fused silica wafer 
before electrode patterning. Carbon nanotubes have been used for a long time to 
increase the area of enzymatic fuel cells (Davis et al., 1997). Some groups have 
developed and characterized electrodes with embedded multiwall carbon 
nanotubes (Prilutsky et al., 2010) but have yet to be implemented in non-
enzymatic glucose fuel cell systems.  
 
4.5 Methods 
4.5.1 Fabrication 
 The fabrications steps for the fuel cells described here were performed at the 
Cornell Nanofabrication Facility. 500μm thick fused silica wafers were used due 
to the fact that electrode can be patterned directly on them without the need of 
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depositing a silicon oxide layer. The electrodes were patterned one at a time 
using a LOR lift-off process. First the anode was patterned using E-beam 
evaporation (CHA Evaporator) where 20nm of titanium was deposited in order 
to promote adhesion followed by 100nm of platinum and 300nm of nickel. The 
wafer was subsequently annealed for 2 hours in nitrogen gas at 600°C (MRL 
Industries Furnace). In order to avoid oxide formation when opening and closing 
the furnace door, the stand-by temperature of the furnace was kept bellow 300°C. 
In order to obtain a high surface area Raney-type surface the nickel was etched 
by keeping the wafers in a 1:1 solution of concentrated sulfuric acid and nitric 
acid for 12 h. The cathode was patterned using E-beam evaporation of 20nm of 
titanium followed by 100nm of platinum and 100nm aluminum. The wafer was 
subsequently annealed for 1 hour in nitrogen gas at 300°C followed by the 
etching the aluminum in 0.1M NaOH solution. The fused silica wafers were then 
diced (K&S 7100 Dicing Saw) into 10mm by 12mm pieces. Copper wires (30 
gauge) were soldered directly onto the electrodes. 
 
4.5.2 Cleaning and activation 
 After dicing the fuel cells were cleaned under oxygen plasma for 10min to 
remove any resist residue at the surface. Both electrodes are than subject to cyclic 
voltammetry in 0.5M sulfuric acid solution for 10 cycles at 50mVs-1. Following a 
method previously described by Kerzenmacher et al. the cathodes were subjected 
for 30min to an oxidative current density of 44μAcm-2 in 0.01M phosphate buffer 
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saline solution (Sigma P-5368 0.138M NaCl) with pH 7.4 at 7% oxygen saturation 
without glucose.  
 
4.5.3 Experimental setup and conditions 
 The experimental setup used in this chapter has been previously described by 
the authors elsewhere (Oncescu and Erickson, 2011). All experiments were 
performed in 500mL 0.01M PBS solution (pH 7.4) at 37C. When specified, 
glucose was added at physiological levels of 5 mmol L-¹. The solution was 
replaced after each experiment to ensure low contamination. Two flow meters 
(VWR 0.2–20 SCFM) were used to adjust the ratio of air and nitrogen (Airgas NI-
200) flowing in the solution. In most experiments air was constantly being 
bubbled through at 0.2SCFH to ensure that the oxygen levels remained constant 
throughout the experiment. The measured dissolved oxygen saturation level was 
(21±0.5)%. Where specified 0.6SCFH nitrogen gas was mixed with the air in order 
to decrease the oxygen concentration in solution. The corresponding dissolved 
oxygen level was measured to (7±0.5)% saturation corresponding to the upper 
physiological oxygen saturation level (7% or about 0.06 mM) (Kerzenmacher et 
al., 2010b). The dissolved oxygen measurements were performed using a 
Dissolved Oxygen Pen (850045 Sper Scientific). The solution was stirred for 3 
hours prior to performing current sweep experiments in order to improve 
glucose mixing in the solution, however it was not stirred during the 
experiments.   
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4.5.4 Instrumentation 
 A Keithley 2400 Source-meter was used to apply a current sweep across the fuel 
cells and a Keithley 2000 Multi-meter equipped with a scanner card was used to 
take the voltage measurements of individual electrode potentials versus the 
reference electrode. The current sweep and channel switching was remotely 
controlled using a LABVIEW program. All current sweeps were performed at a 
sweep rate of 18μA h-1, starting 0μA and increasing the current by 0.5μA every 
100s. A silver–silver chloride reference (Aldrich Double junction Ag/AgCl 
reference) electrode was used as the reference against which electrode potentials 
were measured. 
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Chapter 5 
Smartphone health accessory for colorimetric 
detection of biomarkers in sweat and saliva1 
5.1 Abstract  
The mobile health market is rapidly expanding and portable diagnostics tools 
offer an opportunity to decrease costs and increase the availability of healthcare. 
Here we present a smartphone based accessory and method for the rapid 
colorimetric detection of pH in sweat and saliva. Sweat pH can be correlated to 
sodium concentration and sweat rate in order to indicate to users the proper time 
to hydrate during physical exercise and avoid the risk of muscle cramps. Salivary 
pH below a critical threshold is correlated with enamel decalcification, an acidic 
breakdown of calcium in the teeth. We conduct a number of human trials with 
the device on a treadmill to demonstrate the ability to monitor changes in sweat 
pH due to exercise and electrolyte intake and predict optimal hydration. 
Additionally, we perform trials to measure salivary pH over time to monitor the 
effects of diet on oral health risks.  
 
1Oncescu, V.*, O’Dell, D.*, Erickson, D., “Smartphone based health accessory for 
colorimetric detection of biomarkers in sweat and saliva” Lab-on-a-Chip (2013 
Accepted) 
*These authors have contributed equally to this paper. 
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5.2 Introduction    
 
The cost of healthcare in the U.S. projected to reach 30% of the GDP by 2040 
(Fogel, 2009). The widespread adoption of smartphones among nearly all age 
and income groups presents an opportunity for the development of mobile 
health applications and accessories for these devices that can help reduce costs 
and improve the accessibility of healthcare. Over 40,000 mobile health 
applications (commonly referred to as “apps”) are currently available and that 
number is expanding rapidly (Fox and Duggan, 2010).  A number of consumer 
mobile health accessories that integrate with smartphones such as Nike 
FuelBand, Fitbit One, and Misfit Shine combine accelerometers, heart rate 
monitors, and data on oxygen consumption to give users information on physical 
activity and daily calorie expenditure. Despite the amazing pace of 
developments in mobile health technologies, however, the vast majority of 
devices on the market focus exclusively on these physical measurements.  
A high-impact area for mobile health, that has not yet taken off commercially, is 
in the development of biochemical portable diagnostics tools (Martinez et al., 
2010). Smartphone accessories for the detection of biomarkers in bodily fluids 
could greatly reduce the cost of medical testing and increase global access to 
healthcare. Several academic groups are currently developing smartphone 
platforms for biomarker detection. Recently, Coskun et al. have developed a 
testing platform that can be used at home to test foods for peanut traces and 
other common allergens (Coskun et al., 2013b). Several other groups are working 
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on smartphone-based image processing for quantifying colorimetric changes on 
paper-based immunoassays (Shen et al., 2012).  
In this chapter, we demonstrate an integrated smartphone accessory for 
monitoring changes in sweat and salivary pH. In addition, numerous academic 
publications have also studied the relationship between pH and various 
physiological conditions. For example, salivary pH is an important factor on 
enamel decalcification (Dawes, 2003; West et al., 2008) and sweat pH can be used 
to indicate the risk of dehydration (Morgan et al., 2004).   
The smartphone accessory presented here has an integrated design that allows 
noninvasive real-time analysis using disposable test strips. In this chapter, we 
first introduce the system and how it integrates with existing smartphones. 
Second, we describe the software for colorimetric detection and the method 
through which we ensure uniform repeatable results on different smartphones. 
Finally, in the results section, we show the applicability of our system to sweat 
and saliva biomarker detection through a series of human trials. We demonstrate 
that our system can be used in the context of sweat testing in order to prevent the 
risk of dehydration and to improve performance during physical activity and in 
the context of saliva testing can be used to evaluate the impact of diet changes on 
oral health. 
 
5.3 Methods  
5.3.1 Overview of the system   
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The system presented here consists of a smartphone case, application, and test 
strips. The case has a slot in which a test strip can be inserted for colorimetric 
analysis using the cellphone camera and a space to store up to 6 additional test 
strips. Fig. 5.1 shows a user removing a test strip from the storage space, 
collecting a sweat or saliva sample, and inserting the test strip in the device for 
analysis.  The test strips incorporate 3 different elements inserted in a 3D printed 
support: an indicator strip, a reference strip and a flash diffuser. As an initial 
application presented here, we have designed the test strips in order to measure 
pH differences in sweat and saliva. The indicator strip consist of a 9 mm by 4 mm 
cutout of a pHydrion Spectral 5.0 to 9.0 plastic pH indicator strip for sweat 
testing and a 1.0 to 14.0 strip for saliva testing. The reference strip is made of 
white plastic material and is used in order to detect changes in white balance on 
the iPhone camera due to different light conditions or user error. The flash 
diffuser consists of a 2 mm thick membrane of polydimethylsiloxane(PDMS). The 
purpose of the flash diffuser is to reduce variations in the reading for different 
lighting conditions and will be explained in the calibration section of this 
chapter. It allows light from the smartphone’s flash to diffuse and illuminate the 
back of the tests strip uniformly. In addition, the case is 3D printed using opaque 
Vera black material in order to isolate the test strip from variable external light. 
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Figure 5.1 System for colorimetric quantification of biomarkers in sweat and 
saliva a) Picture of the device with the user removing a test strip from the back 
storage compartment. b) Sweat sample acquisition by application of the test strip 
on the forehead or saliva sample acquisition by user spitting on the test strip. c) 
Insertion of the test strip in the optical system for reading. d) Analysis of the pH 
once the test strip is inserted using the iPhone app.  
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5.3.2 Smartphone application   
To work with the accessory, we have developed a software app to handle image 
acquisition and processing, and data storage and manipulation. The app shown 
in Fig. 5.2 works as follows. First, upon loading the app, the user selects the test 
strip being used from a menu of different biomarker tests available, and the app 
loads the appropriate calibration data and user interface. Secondly, the user 
inserts the disposable test strip cartridge into the hardware accessory and 
touches the “Analyze” function on-screen. Thirdly, the app turns on the camera 
flash and takes an image of the test strip. The quantitative biomarker 
concentration is determined from the image (see “Colorimetric quantification” 
section) and displayed on screen in under five seconds. If pertinent to the specific 
biomarker, additional post-processing is also done from the biomarker results, 
and these results are displayed alongside the biomarker concentration. Finally, 
by swiping left, a scatter plot of the results is generated to show trends over time. 
If desired, the data set can also be sent via email for later viewing or additional 
analysis.      
 
5.3.3. Colorimetric quantification 
Although the ubiquity of smartphones with high-quality integrated cameras 
make such devices ideal for point-of-care biomarker detection, the wide range of  
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Figure 5.2 App and algorithm for quantification of biomarkers.  An overview 
of the modular smartphone app and its operation. a) The user selects the desired 
test strip from a menu of pre-calibrated test options. b) The app automates the 
process of image acquisition and processing for the desired application. The top 
image shows the sweat pH and electrolyte interface; the bottom, the salivary 
monitoring interface. c) A plot of the data is produced to demonstrate trends 
over time. (d) A schematic overview of the image acquisition and processing 
algorithm. 
(d)
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variations across different devices and of test strip illumination present 
significant challenges to accurate colorimetric quantification. Other investigators 
have addressed this problem by calibrating for ambient light conditions through 
conversion to color spaces which are less sensitive to changes in brightness5, 9. On 
its own, this approach still requires uniform external illumination, and false 
colorimetric readings can be made if the phone is not placed at the proper 
distance from the test strip (Shen et al., 2012). One of the unique opportunities of 
smartphone-based colorimetric detection for portable diagnostics, however, is 
that image acquisition can instead be automated, so that the test strip is always 
held in the ideal position and imaged in the same manner, and the data is not 
easily affected by deviations in user protocol. Our device is isolated from 
ambient light with the hardware accessory and diffuses light from the 
smartphone camera flash for reproducible and uniform illumination, improving 
measurement accuracy and minimizing the potential for user error (see 
“Calibration” for details).  
While the use of the camera flash instead of external light removes much of the 
variability from the image acquisition, there are additional steps which must be 
taken for accurate quantitative processing. Although the image from the 
smartphone camera is initially defined with RGB (red green blue) values, 
individual red, green, and blue channels do not correlate well with pH over the 
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range of a universal indicator strip. Nevertheless, the RGB values can be readily 
converted to an alternate color space that matches the color spectrum of the test 
strips more closely. We chose to convert to hue, which unlike RGB was found to 
monotonically increase with pH in our experiments over the entire range of the 
colorimetric test strips used. This advantage of the hue value over RGB for 
smartphone-based colorimetric imaging has also been recently demonstrated by 
Chang (Chang, 2012). In addition, recent work by Cantrell et al. has also found 
hue to be more precise than RGB values for quantitative analysis and less 
sensitive to variations in illumination, making it an ideal candidate for our 
colorimetric test strip analysis (Cantrell et al., 2010). After an initial calibration to 
determine the relationship between the hue and the analyte concentration for 
each test strip, this single hue value is sufficient to quantitatively specify the 
color with a high degree of accuracy.  
The process of image analysis is as follows. When the “Analyze” button is 
pressed, the smartphone app activates the camera flash, and an image is 
captured and stored first as an RGBA (red green blue alpha) byte array. The 
alpha channel, which is a measure of transparency, is discarded as it does not 
vary with analyte concentration.  The RGB array is split into two sections—the 
first, corresponding to the upper colorimetric test strip, and the second, to a 
lower reference region of known color value which is used to compensate for 
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variations between different smartphone cameras and from automated camera 
adjustment functions such as white balance. A 256 x 256 pixel square is selected 
from the center of each of these sections, and the hue value is calculated for each 
pixel from the RGB channels. The hue values are sorted, and the median value is 
chosen to minimize any remaining edge effects which are not removed by the 
PDMS flash diffuser. Because the color of the plastic reference section should not 
change between experiments if the device works correctly, the image acquisition 
process is restarted if the reference hue value varies from the expected calibration 
value by more than 5. This serves to eliminate the possibility of a user protocol 
error—if the test strip is inserted incorrectly and the strip is not optically isolated, 
the reference check will fail and the data will not be stored. If the reference check 
is passed, the test hue value is converted into an analyte concentration by means 
of a measured calibration curve and the relevant biological information is 
displayed on-screen immediately. A schematic of this process is given in Fig. 
5.2d. 
 
5.3.4 Calibration  
The correlation between hue and pH is built into the application, allowing users 
to run tests without additional calibration. This is possible because the case is 
design in a way that minimizes the effect of external lighting as was previously 
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discussed. Fig. 5.3a illustrates the design of the case around the camera and flash 
that allows for uniform lighting of the test strip. By guiding the flash light 
through the PDMS diffuser on the strip and behind the test strip, we avoid the 
need to build in a lighting element, such as an LED, that would make the system 
bulkier and require power input. The strip is imaged at a distance of 2.20 mm 
from the smartphone’s camera and the whole optical piece has a depth of 4.90 
mm. The relationship between hue and pH for our test strips was established 
using buffer solutions and a pH electrode (VWR SympHony SB70P) for an 8 
point calibration. Fig. 5.3b shows the variations in hue readings for 3 different 
iPhones (models 4 and 4S). The same test strip and holder were used at a given 
pH for all three iPhones meaning that the differences can be attributed directly to 
differences in the hardware of the iPhones. A third order polynomial was fitted 
through the data points in order to obtain a correlation between pH and hue. Fig. 
5.3c shows the maximum deviation of the measured pH from the calibrated 
values. It was found that the variation between phones is the largest source of 
error, therefore defining the accuracy of the system over the range of 
physiologically relevant pH values to be within 0.2 pH units. 
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Figure 5.3 Smartphone accessory and application across different smartphones. 
a) Test strip imaging with the first image showing the insertion of the test strip 
and the second one showing a cross sectional view of the optical system b)Hue-
pH correlation for 3 different phones. c) Maximum deviations for three different 
iPhones from the measured calibration curve.  
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As explained previously, in order to further improve the accuracy of our system, 
we incorporate a white reference strip on our test strip. A large variation in the 
hue value of the white reference indicates a failed measurement, possibly from a 
faulty or incorrectly inserted test strip. If the application detects an abnormal hue 
value, it rejects the data point and signals to the user to take another reading. 
Although the system shown here was designed for and prototyped on the iPhone 
4 and 4s, it could easily be ported to any other smartphone platform with a 
CMOS camera. Even if there are systematic differences in camera function and 
sensitivity between smartphones from different manufacturers, these differences 
can be corrected by calibrating the hue-to-pH conversion function once for each 
smartphone model used. If the hardware accessory is re-designed to fit over the 
camera and properly re-calibrated, the most important metric for determining 
the accuracy of the device should still be the variation between several phones of 
the same model, as described above.  
 
5.4 Results and Discussion 
5.4.1 Sweat monitoring for hydration and electrolyte loss 
It is generally well-accepted that dehydration can negatively impact performance 
during exercise (Murray, 2007), however over-hydrating is similarly dangerous 
since it can lead to hyponatremia, a disorder resulting from abnormally low 
sodium plasma concentrations (Murray et al., 2003; Rosner and Kirven, 2006). 
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Hyponatremia has resulted in deaths both in athletic competitions and on the 
battlefield(TP and DE, 1999), due to a disruption in the osmotic balance across 
the blood-brain barrier, resulting in a rapid influx of water into the brain. In 
addition, studies have shown the sodium concentration of sweat can be used to 
evaluate the risk muscle cramps in athletes (Eichner, 2007; Stofan et al., 2005). 
There is currently no system for accurately monitoring hydration levels or sweat 
sodium concentrations during exercise. However, there have been several 
studies showing the correlations between sweat pH and sodium concentration, 
as well as pH and sweat rate (Buono et al., 2007; Emrich et al., 1968; Patterson et 
al., 2000). Therefore, by accurately measuring changes in sweat pH during 
physical exercise, we can determine an optimal hydration strategy.  
In a recent paper, Curto et al demonstrated continuous, smartphone-based sweat 
pH monitoring using a wearable microfluidic platform (Curto et al., 2012). A 
wearable colorimetric pH sensor that can be incorporated directly into clothing 
has some obvious benefits; there are, however, applications in which a discrete 
sensing system with disposable cartridges, such as the one presented here, could 
be more appropriate. The unique use of the diffused smartphone flash in our 
system allows for easy and consistent imaging, even in the absence of external 
light. Moreover, the image processing algorithm was designed to require 
minimum computational power and is performed in real-time directly on the 
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smartphone, without the need to transfer and process the data on an additional 
computer. While a robust wearable sensor is likely more cost-effective than 
disposable strips for a single application, the same accessory presented here 
could also be used to measure various additional biomarkers in sweat, saliva, or 
urine, which could ultimately be more cost-effective for an end user than 
needing separate microfluidic devices for each desired application. 
In order to test the system and observe pH changes during exercise we have 
performed several experiments with users running on a treadmill between 30 
and 60 min. The goal was to show that pH variations during exercise are 
significant and can indicate something about the intensity of the exercise. The 
participants in this study were all males between the ages of 25 and 37 who run 
regularly and participate in competitive racing events. Fig. 5.4a shows pH 
variations at 3 different run intensities for one user. It shows that at high exercise 
intensities, characterized by an increased sweat rate, the pH reaches less acidic 
levels. Fig. 5.4b shows the variations in pH between 3 users running at the same 
speed of 6mph for 30min. The results indicate that different users exercising in 
similar ways would need to exert different levels of effort. Fig. 5.4c shows the 
effect of cooling down by drinking 20 fl. oz. Gatorade at 40 min during 60 min 
runs.  This is expected since sweating is the body’s method to regulate its  
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Figure 5.4 Sweat pH and sodium variations during physical exercise a) pH and 
sodium concentration variations for runs at different intensities b) Variations 
between 3 different users running at 6mph c) Effect of cooling down with intake 
of 20 fl oz of Gatorade 40min into the run for one user. Sodium levels are derived 
from ref [16] d) Hot yoga trials showing pH variations for 4 users during regular 
exercise. Red line show variation for a user who started hydrating at 10min and 
maintained constant exercise and regular hydration for the reminder of the trial   
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temperature (Wyss et al., 1974). Drinking cold fluids decreases the sweat rate and 
affects the sweat pH. 
Because sweat pH has previously been correlated to the concentration of sodium 
(Patterson et al., 2000), the experimental measurements of pH presented here also 
give the approximate sodium concentration of the sweat at each stage 
throughout the run. The sodium concentration is shown on the right y axis in all 
the experiments in Fig. 5.4. It has also been found that the concentrations of the 
constituent electrolytes in sweat vary proportionally with sweat rate (Buono et 
al., 2007; Emrich et al., 1968). By combining these results, an estimate of both the 
sodium and water losses over time due to sweating can be obtained. Since 
different users respond to exercise in different ways, there can be no universal 
guidelines for hydration and electrolyte intake. Using this system to monitor pH 
and sodium concentration allows for a better estimation of the fluid and 
electrolyte intake needed to fully replenish losses.  
Additional experiments were performed to monitor the variations in sweat pH in 
other athletes, such as hot yoga practitioners. Hot yoga is the practice of yoga in 
hot and humid conditions which allows for easy sample collection and analysis. 
The users involved in these test trials were all women between 21 and 49 who 
perform hot yoga more than once a week. The users were instructed to perform 
exercises at their own pace and hydrate at their will. In Fig. 5.4d we show 
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variation in sweat pH for the 4 users. The user highlighted in red only started 
hydrating at the 10min mark and maintained a constant exercise pace after, 
hydrating regularly before cooling off during the last 5min of the trial. The test 
trials which lasted up to 70 min show the expected patterns of pH variations due 
to hydration and cooling down periods. The maximum variations were under 1 
pH unit and the changes in pH are extremely sensitive to changes in user 
intensity and hydration. These test trials demonstrate the advantage and 
applicability of discrete sweat pH measurements in non-continuous forms of 
athletic activity. These sudden changes in pH can be easily monitored using the 
system presented here and analyzed directly on a smartphone.   
 
5.4.2 Saliva pH monitoring for preventing enamel decalcification 
Another important application for pH monitoring is in preventing enamel 
decalcification. There have been numerous studies describing the effects of pH 
on oral health, more specifically on the dissolution of calcium hydroxyapatite, 
the main inorganic component of dental hard tissues (Gore, 1938). It is believed 
that enamel decalcification occurs below a certain critical pH that has previously 
been experimentally determined to be around 6.2 (Fosdick and Starke, 1939). 
More recent papers describe the critical pH as a function of calcium 
concentration in saliva (Anderson et al., 2008).       
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Here we demonstrate the potential of our system to monitor changes in salivary 
pH through the day. Data from one user during a typical day, from early 
morning (at t= 0h) until night (at t= 16h), is presented in Fig. 5.5a. Periods of food 
intake resulted in a rapid increase in pH and are highlighted in blue on the plot. 
Ultimately, the objective of salivary pH monitoring is to enable people to 
estimate their risk of enamel decalcification and to make suitable changes in their 
diet. For this purpose, estimating the amount of time the salivary pH is above a 
certain value is important. Fig. 5.5b gives this data for 3 different users (all males 
between the ages of 25 and 37) during a typical day. Figure 5.5c shows the 
impact of diet on saliva pH for one user. Dental research has shown that bacterial 
interaction with carbohydrates in the mouth results in the formation of 
acids(Ludwig and Bibby, 1957). The variations between users are a result of 
differences in diet and exercise, as well as innate metabolic differences. Changes 
in diet for each user, however, have a marked impact on the salivary pH over the 
course of the day. By monitoring the salivary pH of one user on an ordinary and 
carbohydrate-rich diet (Fig. 5.5c), we can see the effect of carbohydrate-induced 
acid formation on average salivary pH. The device thus offers the potential for 
personalized tracking of the effects of various lifestyle changes over time. On a 
typical balanced diet, the user is above the critical threshold of 6.2 pH for nearly 
100% of the day, but this drops down to only half the day on a carb-rich diet,  
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Figure 5.5 Saliva pH variations over the course of a day a) Variations in saliva 
pH over the course of a day for one user. The colored bars indicate periods of 
food intake. b) Fraction of the day above a certain pH (data for 3 users) c) 
Variation in pH for one user on two different diets  
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resulting in a substantially greater risk of enamel decalcification. These results 
indicate that the effect of changes in diet can be accurately measured with our 
device, thus allowing users to make the necessary dietary adjustments in order to 
improve oral health. 
 
5.5 Conclusion  
In this chaper, we have presented a smartphone accessory and app for 
monitoring pH in sweat and saliva. Sweat pH monitoring is important for proper 
hydration during physical exercise, while saliva pH monitoring can help users 
make changes in their diet to prevent enamel decalcification. We have shown 
through a series of human trials that our system can be used in the context of 
sweat testing in order to prevent the risk of dehydration and to improve 
performance during physical activity. In the context of saliva testing, it can be 
used to evaluate the impact of dietary changes on the risks of enamel 
decalcification and overall oral health.  
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Chapter 6 
Cholesterol testing on a smartphone1  
 
6.1 Abstract 
Home self-diagnostic tools for blood cholesterol monitoring have been around 
for over a decade but their widespread adoption has been limited by the 
relatively high cost of acquiring a quantitative test-strip reader, complicated 
procedure for operating the device, and inability to easily store and process 
results. To address this we have developed a smartphone accessory and software 
application that allows for the quantification of cholesterol levels in blood. 
Through a series of human trials we demonstrate that the system can accurately 
quantify total cholesterol levels in blood within 60 sec by imaging standard test 
strips.  In addition, we demonstrate how our accessory is optimized to improve 
measurement sensitivity and reproducibility across different individual 
smartphones. With the widespread adoption of smartphones and increasingly 
sophisticated image processing technology, accessories such as the one presented 
here will allow cholesterol monitoring to become more accurate and widespread, 
greatly improving preventive care for cardiovascular disease.     
1 Oncescu, V., Erickson, D. "Cholesterol testing on a smartphone" Lab-on-a-Chip 
(2013 Accepted)
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6.2 Introduction  
 
The alarming increase in premature deaths due to heart disease in the developed 
world has resulted in numerous efforts to make blood cholesterol measurements 
accessible outside the clinical setting. (Malhotra and Chaubey, 2003; Murray and 
Lopez, 1997) It is estimated that 60% of adults in the US have high cholesterol 
(over 200 mg/dl), with 37 million among them having very high cholesterol 
(over 250 mg/dl). (Eckert et al., 2007) Long-term studies on the effect of serum 
cholesterol on coronary heart disease mortality indicate that there is a 17% 
increase in mortality rate for every 20mg/dl increase in serum cholesterol levels 
above 210mg/dl. (Verschuren et al., 1995) Monitoring cholesterol levels is 
important because it can empower people to make lifestyle choices for 
preventing heart disease later in life. For some people, improving diet and 
increasing exercise is enough to lower overall cholesterol, but in some cases 
medication needs to be prescribed. Products such as Cardiochek PA (Polymer 
Technology Systems Inc, Indianapolis, USA) and Cholestech LDX (Hayward, 
USA) have been on the market for over a decade; however home cholesterol 
testing is still not common. (Whitehead et al., 2013) A recent study suggested that 
current cholesterol kit users are interested in easier ways of tracking results and 
that they would test more frequently if supplies were more affordable.(Mintel, 
2010) The accuracy of those devices is also a major user concern and has been 
addressed in several publications. (Rubin et al., 2003; Shemesh et al., 2006; Stein 
et al., 2002)       
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Smartphones have the potential of addressing all these issues by eliminating the 
need for separate test kits. The test strips could be imaged directly on a 
smartphone and the processed data can be stored for tracking or sent via e-mail 
directly to a physician. Increasingly sophisticated camera technology on 
smartphones can also improve the accuracy of cholesterol monitoring. 
Smartphone accessories for the detection of biomarkers in bodily fluids have 
been the subject of extensive investigation because they have the potential of 
greatly decreasing the cost and increasing the availability of heath care in the 
world. (Ozdalga, 2012; Zhu et al., 2012) In a recent paper we have demonstrated 
a system for colorimetric monitoring of biomarkers in sweat and saliva. (Oncescu 
et al., 2013) Several academic groups are also developing smartphone platforms 
for biomarker detection (Coskun et al., 2013b) and smartphone-based image 
processing for quantifying colorimetric changes on paper-based immunoassays. 
(Malhotra and Chaubey, 2003; Murray and Lopez, 1997; Shen et al., 2012) 
In this chapter we present and characterize our smartCARD - smartphone 
Cholesterol Application for Rapid Diagnostics – system. The system can quantify 
cholesterol levels from colorimetric changes due to cholesterol reacting 
enzymatically on a dry reagent test strip. It consists of a smartphone accessory 
that allows uniform and repeatable image acquisition of the test strip and an app 
that analyzes parameters such as hue, saturation and luminosity of the test area, 
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quantifies the cholesterol levels and displays the value on the screen. In the 
Methods section, we begin by discussing how the accessory was optimized to 
improve the accuracy and sensitivity of the colorimetric reaction imaging 
process. We then discuss the correlation between cholesterol and different image 
parameters such as saturation and luminosity before presenting the algorithm 
used to process those parameters and calculate the blood cholesterol levels.  In 
the Results section, we present a series of human trials using the device and 
characterize the accuracy of the system and reproducibility of the measurements 
across different smartphones. We conclude by discussing how the system and 
the test strips can be further improved to increase test accuracy and 
reproducibility. 
  
6.3 Methods  
6.3.1 Smartphone accessory for colorimetric analysis  
The smartCARD accessory attaches around the camera of the smartphone as 
shown in Fig. 6.1a. It has been designed to allow quantification of the cholesterol 
colorimetric reaction that occurs on a dry reagent test strip over the entire range 
of physiological cholesterol values. We have investigated different designs and 
types of lighting sources in order to increase the robustness of the system and  
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Figure 6.1 smartCARD accessory a) picture of the smartCARD accessory and the 
test strip used; the inset shows the inside of the accessory with the black PDMS 
diffuser. b) variation in saturation across a 200px area in the center of the low 
cholesterol (<100mg/dl) test strip for different diffusers in the smartCARD c) 
variation in lightness across a 200px area between the low cholesterol 
strip(<100mg/dl) and high cholesterol (>400mg/dl)  strip for 2 different diffusers. 
The bottom of the figure shows the legend for different diffusers used as well as 
the 2 test strips used for the data    
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ability to deal with misalignment of the test strip. In the end, we opted to use the 
smartphone’s flash to illuminate the strip as it provided more uniform lighting 
for accurately imaging the colorimetric reaction on the test strip. Typical 
smartphone acquired images of the colorimetric reaction, at low (<100mg/dl) and 
high (>400mg/dl) cholesterol concentrations are shown at the bottom of Fig. 6.1.  
In order to improve the sensitivity of the system to variations in the color of the 
test strip and to reduce the effect of test strip misalignment into the device, we 
have incorporated a light diffuser over the flash as can be seen in the inset of Fig. 
6.1a. The effect of integrating different diffusers in the smartCARD on the 
measured saturation values at different points on the detection area is shown in 
Fig. 6.1b. It can be seen that at low cholesterol concentrations a light diffuser is 
needed so that the color change can be quantifiable. When no diffuser is used or 
only PDMS is used the strips appears as white with either 100% or 0% saturation 
levels. Diffusers made of black PDMS and FullCure, an acrylic-based 
photopolymer material, allowed for the saturation value on the low cholesterol 
test strip to be quantifiable with standard error of 0.16% and 0.42% respectively 
across a 200px section at the center of the strip. This is important because it 
indicates that misalignment of the test strip will have little effect on the measured 
saturation value.  
The sensitivity of the image acquisition system, defined as the ability to 
differentiate between colorimetric test strips at different cholesterol 
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concentrations has also been investigated. As can be seen in Fig. 6.1c the 
smartCARD accessory with the black PDMS diffuser has on average a 36.6% 
point decrease in lightness when imaging the high cholesterol test strip 
compared to the low cholesterol one. The effect is much lower, only 5.2%, when a 
FullCure diffuser is used. Consequently, black PDMS was used as the diffuser 
material because it not only allows for uniform illumination of the strip but also 
maximizes the range of colorimetric variation on the strip      
The test strips used in this section are dry reagent strips manufactured by 
CardioChek (Polymer Technology Systems Inc, IN, USA). When the user applies 
a drop of blood on one side, it first goes through a series of filter papers that 
separate plasma from red blood cells and direct some of the plasma towards an 
analyze-specific reaction pad. At that point, HDL is separated from LDL and 
VLDL fractions and precipitated by the reaction with phosphotungstic acid. An 
enzymatic reaction then converts total cholesterol and HDL cholesterol to 
cholest-4en-3-one and hydrogen peroxide. The peroxide then reacts with 
disubstituted aniline to form quinoneimine dyes (Eckert et al., 2007; Shephard et 
al., 2007). The color change from the last reaction is then imaged inside the 
smartCARD accessory by the smartphone camera.  
 
6.3.2 Correlation between cholesterol levels and colorimetric reaction 
In order to quantify the colorimetric reaction and to obtain the blood cholesterol 
concentration value, we have developed a calibration curve linking cholesterol to 
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the HSL (Hue Saturation Lightness) cylindrical-coordinate representation of the 
RGB (Red Green Blue) color values at the center of the cholesterol test strip. The 
advantage of using HSL coordinates over RGB for smartphone-based 
colorimetric imaging has been demonstrated in several publications (Cantrell et 
al., 2010; Chang, 2012; Oncescu et al., 2013; Verschuren et al., 1995). Hue (H) has a 
piecewise definition and in the region of interest of the cholesterol colorimetric 
reaction can be written as a function of the red (R), green (G) and blue (B) color 
values:  
        H = (B-R)/C + 2   if M= G         or           H = (R-G)/C + 4 if M= B  (6.1) 
In the equation above C=M-m where M= max(R,G,B) and m=min(R,G,B). In 
addition the lightness (L) and saturation (S) are described by the following 
equations: 
                                               L = ½ (M + m)     (6.2) 
                                               S = (M-m) /(1-|2L-1|)     (6.3) 
For the calibration curve, human serum (Sigma Life Science, USA) was used and 
augmented using Cholesterol Lipid Concentrate (Rocky Mountain Biologicals 
Inc, MT USA) in order to cover the whole range of physiological cholesterol 
levels. At each cholesterol concentration in the relevant physiological range 
(140mg/dl to 400mg/dl) the test strip was first analyzed using the CardioChek 
portable Blood Test System and then imaged using the smartCARD system. In 
Fig. 6.2a we show the variations in lightness and saturation for images acquired 
using the smartCARD system. The cholesterol reading is first obtained using the  
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Figure 6.2 Relationship between image HSL and cholesterol levels a) variation 
in lightness (red) and saturation (black) vs cholesterol levels b) predicted 
cholesterol concentration versus actual cholesterol concentration defined by 
CardioCheck PA 
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CardioChek portable Blood Test System. The hue values show very little 
variation across the whole range of cholesterol values and are not shown in Fig. 
6.2a. However, as we will show later in the Results section, hue values can be 
used to indicate if a test is successful or if it fails due to image acquisition or test 
strip issues. The relationship between concentration and saturation can be 
described by a second order polynomial. 
   [Chol] = 0.08S2-4.56S+196.84    (6.4) 
 As can be seen in Fig. 6.2b this allows almost perfect matching with a maximum 
error of 1.8%.  
 
6.3.3 Smartphone image acquisition and processing   
Several groups have developed algorithms for test-strip colorimetric analysis on 
a smartphone and have demonstrated their application measuring simple 
colorimetric reactions such as pH (Oncescu et al., 2013; Shen et al., 2012; 
Whitehead et al., 2013). In those cases instantaneous reactions make it easy to 
image. Slow enzymatic reactions involving whole blood separation steps such as 
for cholesterol monitoring have the additional complication of being time 
dependent and more variable due to strip manufacturing variability. For such 
cases, Mohapatra et al. (Mintel, 2010; Mohapatra and Phillips, 2013) has proposed 
using a personal glucose meter to quantify active enzyme analytes as a way of 
reducing the effects of lighting conditions, focus and camera differences. Other 
groups have focused on improving the algorithm for image processing and 
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combining it with an accessory that block external lighting for the analysis of 
time varying reactions such as fluorescent assays (Coskun et al., 2013a; Rubin et 
al., 2003; Schwaebel et al., 2013; Shemesh et al., 2006; Stein et al., 2002). 
Here we have developed a smartphone application for the iPhone iOS platform 
that in combination with the smartCARD accessory allows for image acquisition 
and colorimetric analysis of the cholesterol enzymatic reaction. A screenshot of 
the app is shown in Fig. 6.3a. When the user presses “analyze” on the app, an 
image of the colorimetric color changes is acquired through the iPhone camera.  
As shown in the Fig. 6.3b schematic, the app then executes several processing 
steps before the cholesterol value is displayed on the screen. First, a 100px by 
100px calibration area is selected at the bottom right corner of the image. The 
average RGB value is computed and converted to HSL. This average HSL value 
is then compared to a reference value and a background shift is computed. The 
whole image is then is subjected to this background shift. After the background 
shift, a 100px by 100px area in the middle of the detection circle is then selected 
and the same computation as before is done to obtain the average HSL value of 
the test area. The algorithm then verifies if the test is valid by comparing the 
average hue value to the typical value of the cholesterol test, which as we will 
show in the Results section is constant across physiological cholesterol values 
(H~ 180) both for serum samples and blood samples during test trials. In order to 
decrease fluctuations due to lighting conditions, the strip is imaged 3 times and  
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Figure 6.3 App and algorithm for cholesterol quantification a) screenshot of the 
app showing current cholesterol reading as well as average reading for one user) 
algorithm used for image processing and implemented in iOS app  
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the average hue value over those 3 images is taken. If the hue value falls within 
the range of expected hue values, than the cholesterol level is calculated using 
the calibration curve obtained in the previous section. The ability of identifying 
bad samples is a major advantage over specialized hand-held devices, such as 
CardioChek PA, that use reflectance photometry to quantify colorimetric 
reaction.  
 
6.4 Results and discussion 
6.4.1 Accuracy and reproducibility  
A critical issue to consider for point-of-care testing is the accuracy of the 
measurement. Once the user applies a drop of blood on the strip it takes some 
time for the colorimetric change to occur on the other side of the strip since the 
blood goes through several separation steps and chemical reactions and the 
colorimetric change occurs gradually as can be seen at the bottom of Fig. 6.4. If 
the strip is imaged before the reaction has terminated then we will get a 
misleadingly low value for the blood cholesterol level. In order to determine the 
approximate time required for the reaction to occur we have monitored the color 
change for a serum sample with an actual concentration of 178mg/dl. As can be 
seen in Fig. 6.4a it takes about 60s for the colorimetric change to stabilize. The 
variation in predicted cholesterol levels are contained within less than 3.9% of  
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Figure 6.4 Accuracy and reproducibility a) variations in predicted cholesterol 
levels vs time for a test strip with the clue horizontal line representing the actual 
cholesterol level of 178mg/dl b) variation in readings with different 3 different 
iPhones. The bottom of the figure shows the imaging of the test strip during the 
first 40s.    
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the actual value after that however the value shifts up as time elapses. It is 
therefore important to be consistent by building in the algorithm a time frame for 
imaging the test strip. In addition averaging several acquired images during that 
time frame can helped further improve the accuracy. Therefore in next section 
the image acquisition is all done between 60s and 80s and the predicted 
cholesterol is the average of the predicted cholesterol on 3 different images. As 
will be shown in the next section the 3.9% inter-assay variation that was 
observed here for the smartCARD system is lower than what was observed for 
other lipid point-of-care device.  
Another important feature of the smartCARD system is that it can be used on 
different smartphone platforms with small variability. Fig. 6.4b shows the 
imaging of the same test strips with 3 different smartphone cameras across a 
wide range of physiological cholesterol values. The maximum difference 
between readings is 5.8% which is significant but on the same order as the 
CardioChek PA system reading error. This error between phones can be 
minimized by designing custom strips that allow for better calibration as we 
showed in our previous publication.         
 
6.4.2 Validation of smartCARD for human trials 
In order to demonstrate the ability the smartCARD system for determining blood 
cholesterol levels we ran user experiments and compared the predicted 
cholesterol levels to the actual cholesterol levels as indicated by the CardioCheck 
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PA lipid point-of-care device. As can be seen in Fig. 6.5a from the 9 readings 
taken, the maximum difference between our predicted value and the 
CardioCheck PA reading was 5.5% in one instance with less than 3% difference 
for all the other readings.  
For the CardioCheck PA the observed inter-assay imprecision has been recorded 
by Shephard et al. (Ozdalga, 2012; Shephard et al., 2007; Zhu et al., 2012)as 4.4% 
and observed bias with respect to a CDC-certified laboratory method has been 
recorded as 12.1%. Other studies produced similar results for lipid point-of-care 
devices (Carey et al., 2006; Oncescu et al., 2013; Parikh et al., 2009; Stein et al., 
2002). Inter sample and comparative difference for the smartCARD system 
indicates that the error is lower than for such point-of-care systems. 
In addition, the smartCARD algorithm can identify erroneous readings caused 
by misalignment of the test strip in the accessory or insufficient amount of blood 
on the test strip. During the human trials, two readings were discarded because 
the recorded hue didn’t fall within the normal range of hue values (170° to 190°) 
as shown in Fig. 6.5b. A low hue value can indicate that the amount of blood 
applied on the test strip is not sufficient or that the sample was contaminated. 
Further investigation into the reasons why some tests fall outside the normal hue 
range would be useful to improve the system but is beyond the scope of this 
chapter.           
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Figure 6.5 Test trials of smartCARD device and comparison to commercial 
device a) difference between CardioChek PA reading and smartCARD for 
human trails b) Hue differences for all the human test trials showing that 
discarded tests give hue values outside of the normal range (170-190°) 
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6.5 Conclusion  
In this chapter we demonstrate a system that can be used to measure and track 
cholesterol levels directly on a smartphone. The smartCARD system is designed 
in a way that allows for optimal image acquisition. We showed that we can 
obtain cholesterol levels within 1.8% accuracy by looking at the acquired image’s 
saturation.  We also demonstrated interphone repeatability before performing 
user experiments and measuring blood cholesterol levels with the system we 
have developed. The smartCARD predicted cholesterol values for the user 
testing were compared to the measured value using the CardioChek PA system 
and found that the maximum difference between our predicted value and the 
CardioCheck PA reading were less than 5.5% in all cases.  
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Chapter 7 
Conclusion and Future Work  
7.1 Conclusion  
In this thesis we have presented developments in two areas that have the 
potential of revolutionizing medical technology and point-of-care devices .  
One area is that of autonomous implantable devices. Such devices are promising 
for conditions that require constant monitoring such as diabetes, where 
fluctuations in glucose levels can occur at any time, and the administration of 
insulin cannot wait for the user to react. In Chapter 2 we presented such a device 
for the prevention of late-phase hemorrhagic shock (HS). It incorporates a 
nanowire biosensor that allows the continuous monitoring of vasopressin in 
solution, an electrochemical drug delivery system that delivers vasopressin at the 
onset of late-phase HS to stabilize the situation, and a glucose fuel cell to power 
the whole device. The need for a power source to power such autonomous 
implantable devices is discussed extensively in Chapter 3 and 4 of this thesis. 
Given the high-power demand and desired length of implantation of many such 
autonomous devices, lithium batteries cannot continue to be the only source of 
energy. In Chapter 3, we propose a glucose fuel cell that can act as coating layer 
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to many high surface area implantable devices. In Chapter 4 we come up with an 
innovative glucose fuel cell that can be stacked to produce a high power density 
fuel cell unit. That is the fuel cell unit that was used in Chapter 2 to power the 
device for the prevention of late-phase HS.      
The second area that is covered in this thesis is that of smartphone diagnostics. 
There are numerous colorimetric reactions – chemical, enzymatic, gold 
nanoparticle immunoassays – that can be quantified using a smartphone 
platform. In Chapter 5 we demonstrate the general idea by showing that we can 
monitor pH changes in sweat and saliva accurately and precisely across different 
smartphones. The system consists of a test strip, an accessory that goes around 
the camera of the smartphone and that ensures image uniformity and a app 
processes the data and displays it on the screen for the user. We show several 
applications where pH monitoring is useful.    
In Chapter 6 we demonstrate that that the system can accurately quantify total 
cholesterol levels in blood within 60 sec by imaging standard test strips. Finally 
in Chapter 7 we present a novel colorimetric gold nanoparticle-based 
immunoassay for 25-hydroxyvitamin D and demonstrate that can perform a 
vitamin D deficiency testing with the same accurately as commercial ELISA kits. 
   
7.2 Future Developments for Autonomous Implantable Devices  
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7.2.1 Autonomous implantable device for late-phase HS 
Miniaturization and in-vivo testing are the next steps in the development of an 
implantable hemoAID. The operation of the individual components of this 
device, or similar technologies, have been demonstrated elsewhere in-vivo or in 
serum. The vasopressin drug delivery system presented here is based on a 
device, by Chung et al., that allows controlling the rate of drug ejection and has 
been later shown to operate in-vivo in Manduca sexta moths (Chung and Erickson, 
2009). In that work the drug delivery devices are sealed using biocompatible wax 
and implanted in the moths for over 2 days demonstrating stability of 
vasopressin during storage and upon electrochemical ejection. Other groups 
have developed similar micro-electro-mechanical-systems(MEMS) for rapid 
delivery of vasopressin and have demonstrated biocompatibility and long term 
vasopressin storage without degradation (Elman et al., 2009). Some preliminary 
in-vivo studies in rabbits have been reported by H. L. Ho. Duc where a 20µL dose 
of 100µg/kg vasopressin solution is delivered subcutaneously and an increase in 
plasma vasopressin levels was observed to reach a stable concentration after 
about 1h (Duc, 2009). These experiments demonstrate that such drug delivery 
technology is suitable for implantation and that the amount of vasopressin 
required is not an obstacle. The hemoAID reservoir contains approximately 16µL 
of concentrated vasopressin solution (200μM) or approximately 1.4 IU. When the 
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device is loaded with a saturated solution of Arg8-vasopressin (400 IU/mg with 
20 mg/ml solubility (Dawson et al., 1969)) it is able to deliver a maximum of 128 
IU. This falls within the range of vasopressin levels required to temporarily 
maintain a late-HS patient alive as discussed previously. Multiple drug delivery 
reservoirs can be integrated to deliver vasopressin over a longer period of time 
without substantially increasing the volume of the device as was done by Chung 
et al. (Chung et al., 2012).     
In the current form, the device is integrated in a 3cm3 packaging with the fuel cell 
occupying about 1cm3 and the circuitry being external to the device. The 
miniaturization of similar circuitry has been demonstrated by Gumus et al. for 
application in in-vivo uric acid sensing on pigeons[30]. We envision the final 
version of the hemoAID, with multiple vasopressin drug delivery reservoirs, on-
board circuitry and coated in biocompatible wax, to be suitable for sub-
cutaneous implantation (Gumus et al., 2014). 
 
7.3 Future Developments for Smartphone Diagnostics  
 Because the device presented in Chapter 5 allows for reproducible colorimetric 
detection with minimal user error, we believe that such a system could also be 
extended to a wide range of biomarkers for other portable diagnostics 
applications.  
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For the cholesterol device presented in Chapter 6 it is possible to design the 
cholesterol test strips in such a way as to further minimize analysis fluctuations. 
We have demonstrated in a previous publication that by incorporating and 
imaging a white reference area on the test strip, we can adjust the white balance 
and get more reproducible results across different smartphones. (Coskun et al., 
2013b; Oncescu et al., 2013) Finally, using the smartCARD system presented here 
it is possible to measure other commercially available colorimetric test strips for 
LDL, HDL cholesterol, and triglycerides.        
In a paper not presented in this thesis, we have developed a system shown in 
Fig. 7.1 for rapid quantification of vitamin D levels on a smartphone.  This is 
achieved through the development of: a smartphone accessory, app, and novel 
gold nanoparticle (AuNP) based colorimetric competitive direct-antigen 
immunoassay.  
We demonstrate that using this system we can measure physiological levels of 
25(OH)D in solution with accuracy better than 15nM and a precision of 10nM. 
Moreover we show that the results obtained using this system are comparable 
with that of commercial ELISA kits. By analyzing 3 serum samples with 
unknown 25(OH)D concentration we were able to determine accurately the 
severity of the 25(OH)D deficiency in each case. These results are promising for 
tackling the problems associated with vitamin D deficiency both in the 
developed and the developing world. This also opens the door to the 
quantification of numerous immunoassays directly on a smartphone.    
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Figure 7.1 Vitamin D quantification on a smartphone a) accessory for vitamin D 
quantification on a iPhone with the inset showing the components of the accessory b) 
schematic showing surface chemistry on the test strip  
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      Appendix 1 
Single Layer Fuel Cell Microfabrication  
In this section we discuss the detailed microfabrication protocol of the single-
layer fuel cell (SLFC) presented in Chapter 4 of this thesis. 
The fabrications steps for the fuel cells described here and shown in Fig. A1.1 
were performed at the Cornell Nanofabrication Facility. 500μm thick fused silica 
wafers were used due to the fact that electrode can be patterned directly on them 
without the need of depositing a silicon oxide layer. If silicon wafers are used an 
oxide layer needs to be deposited using a GSI PECVD tool. The electrodes were 
patterned one at a time using a lift-off process. First for the anode:  
- Spin S1818 at 2000rpm for 60sec  
- Hot plate for 60sec at 95C 
- Expose for 25sec in ABM   
- Submerge wafer in toluene for 3min (keep agitating) 
- Hot plate for 30sec at 95C 
- Develop in 321MIF for 90sec (repeat if needed another time)  
The anode was patterned using E-beam evaporation (CHA Evaporator) where 
20nm of titanium was deposited in order to promote adhesion followed by  
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Figure A1.1 Fabrication steps for the single layer fuel cell  
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100nm of platinum and 300nm of nickel. The photoresist was then removed so 
that only the patterned anode remained on the wafer by     
- Submerging wafer in 1165 for about 3h (face down with constant stirring) 
The wafer was subsequently annealed for 2 hours in nitrogen gas at 600°C (MRL 
Industries Furnace). In order to avoid oxide formation when opening and closing 
the furnace door, the stand-by temperature of the furnace was kept bellow 300°C.  
In order to obtain a high surface area Raney-type surface the nickel was etched 
by keeping the wafers in a 1:1 solution of concentrated sulfuric acid and nitric 
acid for 12 h.  
For the cathode, the following process was used:  
- Spin S1818 at 2000rpm for 60sec  
- Hot plate for 60sec 
- Expose for 9sec in ABM   
- Submerge wafer in toluene for 3min  
- Hot plate for 30sec  
- Develop in 321MIF for 90sec (repeat if needed another time)  
The cathode was patterned using E-beam evaporation of 20nm of titanium 
followed by 100nm of platinum and 100nm aluminum. Then: 
- Submerge wafer in 1165 for about 3h (face down with constant stilling) 
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The wafer was subsequently annealed for 1 hour in nitrogen gas at 300°C 
followed by the etching the aluminum in 0.1M NaOH solution. The fused silica 
wafers were then diced (K&S 7100 Dicing Saw) into 10mm by 12mm pieces. 
Copper wires (30 gauge) were soldered directly onto the electrodes. 
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Appendix 2 
Vasopressin Biosensor Microfabrication 
A2.1 Reagents and materials 
Arginine vasopressin with with Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 
sequence and lypressin with Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2 
sequence were purchased from American Peptide Company Inc. Aptamer, 55-nt 
single-stranded DNA pool synthesized with the sequence 5’-
TCACGTGCATGATAGACGGCGAAGCCGTCGAGTTGCTGTGTGCCGATGC
ACGTGA, was ordered from Integrated DNA Technologies Inc. COOH-
functionalized multiwall carbon nanotubes were obtained from Cheap Tubes Inc. 
N-hydroxysuccinimide (NHS) and Sodium dodecylsulfate (SDS) were purchased 
from MP Biomedicals LLC, while 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) was purchased from Geno Technology, Inc Sheep Serum 
was obtained from Valley Biomedical Inc. and human serum albumin (HSA) was 
purchased from Sigma-Aldrich Co.  
 
A2.2 Patterning of CNTs and Gold Electrodes on Silicon Wafer 
In this design CNTs were immobilized between two lithographically patterned 
gold electrodes with a gap of 10 µm. A gap of 10 µm was chosen for the CNT 
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pattern because initial experiments have demonstrated increased sensitivity with 
decreasing gap in the 10-50 µm range. First a 4-inch silicon wafer was cleaned 
and oxidized in hot piranha solution in order to generate hydroxyl groups on its 
surface. Microposit S1805 Photo Resist was than spin-coated on the silicon wafer 
surface and the CNT pattern was created using standard photolithography. The 
silicon wafer was then treated in Molecular Vapor Deposition Tool (MVD 100) 
for a 15 minutes (3-aminopropyl)trimethoxysilane (APTMS) deposition to create 
a amine group monolayer on its surface. Carbon nanotubes  dispersed in 0.5% 
SDS solution (0.1 mg/mL) were pipetted on APTMS-treated CNT pattern and 
allowed and allowed to immobilize on the surface at room temperature for three 
hours.  Subsequently, the wafer was oven-baked overnight at 80 °C. 
The gold electrodes were patterned using a standard LOR3A lift-off process. The 
patterned CNTs were aligned with the gold electrode pattern and 5 nm 
chromium/60 nm gold were deposited on the wafer using a e-Beam Evaporator.  
 
A2.3 Surface Modification of Patterned CNT on Silicon Wafer.  
The core of the sensing device is the signal-transducible carbon nanotubes with 
surface modification of aptamers, which are amine-terminated fifty-five base 
oligonucleotides with a cyclic structure. It allows the tight binding of specific 
target, vasopressin molecules. Before the aptamer immobilization, a mixture of 
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0.4 M EDC and 0.1 M NHS in 1:1 volume ratio was pipetted on the CNT-
immobilized pattern of the sensor. The mixture droplets were maintained on the 
pattern for 3 hours at room temperature in order to create an EDC/NHS 
activation layer on which aptamer can effectively be immobilized. Subsequently, 
the sensors were cleaned with DI H2O wash and N2 dry. Aptamer at 1 µM 
concentration was then pipetted on the EDC/NHS-modified CNTs and 
maintained for 24 hours at room temperature for immobilization. The aptamer-
modified sensors were once again cleaned with DI H2O wash and N2 dry. For 
both NHS/EDC and aptamer modifications, 1.5 L of solution droplet was used 
per sensor to cover its detection area entirely.  To prevent the premature drying 
of the droplets, the sensors were kept in a humidified chamber.  
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